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Abstract
The contributions of this thesis are organised in two parts. Part I presents a
mathematical model for drug distribution and drug effect of volatile anaesthe-
sia. Part II presents model predictive control strategies for depth of anaesthe-
sia control based on the derived model.
Closed-loop model predictive control strategies for anaesthesia are aiming
to improve patient’s safety and to fine-tune drug delivery, routinely performed
by the anaesthetist.
The framework presented in this thesis highlights the advantages of ex-
tensive modelling and model analysis, which are contributing to a detailed
understanding of the system, when aiming for the optimal control of such sys-
tem. As part of the presented framework, the model uncertainty originated
from patient-variability is analysed and the designed control strategy is tested
against the identified uncertainty.
An individualised physiologically based model of drug distribution and up-
take, pharmacokinetics, and drug effect, pharmacodynamics, of volatile anaes-
thesia is presented, where the pharmacokinetic model is adjusted to the weight,
height, gender and age of the patient. The pharmacodynamic model links the
hypnotic depth measured by the Bispectral index (BIS), to the arterial con-
centration by an artificial effect site compartment and the Hill equation. The
individualised pharmacokinetic and pharmacodynamic variables and parame-
ters are analysed with respect to their influence on the measurable outputs, the
end-tidal concentration and the BIS. The validation of the model, performed
with clinical data for isoflurane and desflurane based anaesthesia, shows a
good prediction of the drug uptake, while the pharmacodynamic parameters
are individually estimated for each patient.
The derived control design consists of a linear multi-parametric model pre-
dictive controller and a state estimator. The non-measurable tissue and blood
concentrations are estimated based on the end-tidal concentration of the volatile
anaesthetic. The designed controller adapts to the individual patient’s dy-
namics based on measured data. In an alternative approach, the individual
patient’s sensitivity is estimated on-line by solving a least squares parameter
estimation problem.
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1. Motivation and Introduction
During surgery, the anaesthetist faces the task of providing safe anaesthesia
for the patient, while maintaining the vital functions. A mix of administered
drugs leads to the desired effects of hypnosis, amnesia, analgesia and muscle
relaxation. The drug side-effects on the cardiovascular system, the respiratory
system and the central nervous system, if not monitored closely, can have such
a high impact that they are life threatening. Given an enormous variety of
(i) patients differing in weight, height, age, sex and race, (ii) requirements
for surgeries with distinctive impact on the patient and (iii) interactions of
administered agents, the anaesthetist has to keep all these covariates and
influences in mind, while providing anaesthesia with possible complications.
Currently anaesthetists rely on common practice and their personal ex-
perience to determine simultaneous drug administration rates. High-fidelity
modelling and optimised control for drug administration could (i) pave the
way for personalised health care, taking into account the individual patient
characteristics for optimal and flexible drug administration, (ii) guarantee the
safety of the patient minimising side-effects, as well as (iii) provide the anaes-
thetist with additional information about the current anaesthetic state of the
patient, the patient’s vital functions and more time to focus on critical issues.
The modelling and automatic control of anaesthesia is believed to benefit
the safety of the patient undergoing surgery and provide anaesthetists and
researchers with valuable insights, (Bibian et al., 2005; Glass and Rampil,
2001; Hardman and Ross, 2006; Morari and Gentilini, 2001; Struys et al.,
2006).
Motivated by various challenges in automation of anaesthesia, this thesis
focuses on the automation of the hypnotic state of the patient. The presented
steps in this thesis towards a validated control strategy starting with the model
development via model analysis, uncertainty identification and robust control
design are pointed out in the framework in Figure 1.1.
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Figure 1.1.: Framework illustrating the work presented in this thesis.
Anaesthesia is either both induced and maintained by the continuous in-
fusion of an intravenous anaesthetic agent, e.g. propofol, or maintained by
admixture of a volatile anaesthetic agent, e.g. isoflurane or desflurane, to the
inhaled air. Volatile anaesthesia is preferred by most anaesthetists, because
the end-tidal concentration of the volatile anaesthetic is standardly measured
and widely used as an indicator of the hypnotic depth, (Miller et al., 2010)
and (Chapter 2, Figure 2.2). For intravenous anaesthesia, the anaesthetist
relies on the measurement of the hypnotic depth by, for example, the Bispec-
tral Index (BIS), because on-line plasma concentration measurements are not
available. The Bispectral index (BIS) is an empirically derived signal based on
a real-time electroencephalography (EEG) trace acquired from a frontotem-
poral montage. The BIS value indicates the responsiveness of the patient and
ranges from 100 to 0, where 100 describes normal cortical electrical activity
of a fully awake patient, 85-65 sedation, 65-45 general anaesthesia, 45 deep
hypnosis, 40 near suppression, 30-0 increasing burst suppression and 0 cortical
electrical silence, (Miller et al., 2010).
In brief, the objective for control of anaesthesia can be summarised by a fast
and stable maintenance of the hypnotic level, measured by the BIS. The BIS
target values for general anaesthesia lie in-between 40-60, but might be mod-
ified by the anaesthetist. A summary of the control objective is depicted in
Figure 1.2, where CI denotes the concentration of the inhaled volatile anaes-
thetic or the bolus of the infused intravenous anaesthetic. BIS denotes the
measure of the anaesthetic depth and CE the exhaled or end-tidal anaesthetic
concentration, only available for volatile anaesthesia.
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Figure 1.2.: Control objective for intravenous and volatile anaesthesia.
The closed loop state feedback control design for drug delivery of anaesthesia
is illustrated in Figure 1.3. The controller, MPC block in Figure 1.3, computes
the optimal drug concentration or dose u (CI) for the patient to maintain the
reference point yR on the BIS or CE , which is illustrated in Figure 1.2.
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Figure 1.3.: Closed loop control design structure.
The first essential step towards such closed loop control strategy is the
derivation of a mathematical model that adequately describes the system.
Here the challenge is to find the balance between a very complex model and an
over-simplified model. The very complex model is likely to contain too many
parameters that cannot be determined or estimated independently, mainly
due to the lack of measurements and adequate sensors. The over-simplified
model might neither capture the systems dynamics nor allow insights and
understanding of the system. During the modelling process and model design,
the objective of the model development plays a crucial role; in this thesis, the
focus lies on model development for explicit MPC. Hence, the model should
be of a reasonable size to enable the computation of an explicit controller, but
still represent the individual patient’s characteristics.
The pharmacokinetic-pharmacodynamic (PK-PD) model presented in this
thesis contains 7 ordinary differential equations (ODE), presented in Chap-
ter 3. The state space representation (1.1) of the equation system, built based
on this model, has two fixed inputs, one variable input, one output and 7 state
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variables, resulting in a 7-dimensional state vector x ∈ Rn with n=7.
xk+1 = Axk +Buk
yk = f(xk), (1.1)
where k denotes the discrete time points. The state vector, xk, contains the
concentrations in the blood and tissue compartments of the model, uk denotes
the variable input, CI , and yk is the output, BIS. An illustration is given in
Figures 1.2 - 1.3. The non-linearity, f(xk), is introduced by the Hill equation,
which relates the effect-site concentration to the BIS. For the design of a linear
explicit MPC strategy a discrete linear state space system is required:
xk+1 = Axk +Buk
yk = Cxk (1.2)
The strategies to obtain a liner system are (i) the algebraic inverse of the
Hill equation (Gentilini et al., 2001; Ionescu et al., 2008) or alternatively (ii)
piecewise affine approximations of the Hill equation (Chapter 7).
The derived model is implemented and simulated in gPROMS (PSE, 2011)
and shows a good approximation of the pharmacokinetics of isoflurane and
desflurane, whereas the pharmacodynamic parameters were individually esti-
mated for each patient applying the gPROMS (PSE, 2011) parameter esti-
mation entity (Chapter 5). To gain further understanding, all parameters of
the model are analysed with respect to the measurable outputs: the end-tidal
concentration and the BIS. For a global sensitivity analysis parameters and
variables were divided into a pharmacokinetic and pharmacodynamic group
and analysed separately. A further analysis was performed by changing the
parameters one at a time in-between specified bounds to observe the effect on
the output of interest. In the final part of the model analysis, a correlation
analysis of the most influential parameters and variables is presented. This
extensive analysis leads to a very good understanding of the model and its
dynamics and, more importantly, the envelope of uncertainty the MPC has to
handle (Chapter 4). In addition, the model with individually adjusted vari-
ables and parameters can be applied for closed loop control validation, where
the patient block in Figure 1.3 represents a patient of the clinical study.
Given this validated and analysed model, an anaesthesia drug delivery sys-
tem consisting of an explicit MPC is designed that calculates the optimal drug
dose as a function of the derived model. The MPC is designed as a state feed-
back controller. The optimal control input, the drug dose CI , is calculated
based on the system’s states, which are the drug concentrations in the tissue
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and blood compartments. Not all drug concentrations can be easily measured;
hence, a state estimator is required to predict the non-measurable states. The
straightforward choice is to apply the derived state space model and simulate
it simultaneously with the process for identical inputs to obtain the states. As
a second strategy the states are estimated by a Kalman filter based on the
measurement of the end-tidal anaesthetic concentration (Chapter 7).
The choice for the design of an explicit controller via multi-parametric
quadratic programming (mp-QP) is motivated by the possibility of testing
the controller in advance for all occurring scenarios and the full parameter
space, (Bemporad et al., 2002), which complies with the high safety standards
for drug delivery systems of anaesthesia. The mp-MPC is derived in the POP
toolbox for MATLAB, (ParOS, 2004), and designed to adjust to the indi-
vidual patient’s dynamics by an output feedback strategy. As an add-on to
the explicit MPC, an on-line parameter estimation of the PD parameter C50,
which shows the highest sensitivity towards the BIS is presented. Here a least
squares optimisation problem is solved in GAMS (2013) (Chapter 10).
Structure of this Thesis
The structure of this thesis is organised in two parts guided by the frame-
work presented in Figure 1.1. Part I is concerned with modelling of the drug
distribution and drug effects during volatile anaesthesia, model analysis and
validation studies. Part I has been partly published in Krieger et al. (2013).
Part II is illustrating the control design and closed-loop control validation
of the drug delivery system for depth of anaesthesia. Each part contains a
separate literature review.

Part I:
Modelling, Model Analysis
and Model Validation
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Objective and Summary
The objective of this part is to fundamentally understand and analyse the
dynamics of the system: the model for volatile anaesthesia.
Modelling
Model AnalyisModel
Uncertainty
Identification
(Chapter 3,
5 and 6)
Validated model
for closed-loop
control testing.
(Chapter 4)
Most influential
parameters and
variables of
the model.
(Chapter 4)
Envelope of
uncertainty the
control strategy
has to handle.
Figure 1.4.: Modelling framework and contributions presented in Part I.
The objectives and contributions of an extensive analysis leading to a well-
established understanding of the dynamic system model in Figure 1.4 are
further defined as follows:
I) Validated model with clinical data for closed loop control evaluation.▶ Validated model for uptake and distribution of isoflurane and des-
flurane based anaesthesia.
II) In-depth understanding of the influence of the model’s parameters and
variables.▶ Cardiac output and lung volume are the parameters with the highest
influence on the distribution and uptake of the volatile anaesthetic
agent.▶ The pharmacodynamic parameters have the highest influence with
respect to the drug effect; particularly C50 defined as the effect site
concentration at 50% drug effect.
III) Identify the uncertainty for the design of a robust control strategy.▶ The inter-patient variability is very high; particularly for the phar-
macodynamic parameters; hence an off-set free robust control method
or on-line parameter estimation is required to provide safe control.
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2. Fundamentals of Mathematical
Modelling for Anaesthesia
The mathematical modelling of drug distribution and drug effect for a wide
number of drugs, e.g. chemotherapeutic agents, hypnotics and analgesics is
a well established method to help understanding and predicting the mecha-
nisms occurring during and after drug administration. In this context, the
aim is to describe the time course of drug concentrations in the tissues and
the effect on the body by mathematical equations, (Dingemanse and Appel-
Dingemanse, 2007). Equations describing the distribution, absorption, elimi-
nation and metabolism are referred to as pharmacokinetics, whereas the link
of the concentration to the effect is described by pharmacodynamic equations.
2.1. Pharmacokinetic Modelling
Pharmacokinetics describe the distribution of the drug in the human body.
Here, two approaches for pharmacokinetic models dominate the literature,
(i) mammillary compartmental models, where several peripheral compart-
ments are connected to one central compartment, and (ii) physiologically
based pharmacokinetic models, where organs and tissues are interconnected
and arranged copied from physiology. The approach of physiologically based
pharmacokinetic (PBPK) modelling for drug delivery, uptake and distribution
models gains increasing attention of researchers, (Hall et al., 2012), and may
be very detailed down to a systems biology level, (Ghosh et al., 2011).
The probably oldest idea of of describing the human body as a complex inter-
action of flows and plants processing nutrients originates from Kahn (1926),
who imagined the man as a complex industrial machine. In the 1930s Teorell
derived first physiologically based models for drug distribution, uptake and
elimination (Teorell, 1937a,b). Pioneering work towards individual patient
variables of volatile agents for a model mapping the circulation to describe
the uptake of ether in a dog goes back to Haggard, (Haggard, 1924a,b,c).
Regarding the prediction of the uptake of volatile anaesthetics most models
are either based on the work of Mapleson or Eger. Both authors were aiming to
match the measured uptake of the anaesthetic gas by mathematical equations
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to understand the anaesthetic uptake of their patients. The basic idea was to
group tissues with similar properties, such as the well perfused organs, into
one compartment and describe the uptake based on these tissues’ properties,
e.g. drug solubility and perfusion.
(a) PBPK model
Mapleson.
(b) Mammillary PK model Eger. (c) Further subdivision
of one compartment.
Figure 2.1.: Generic structures of pharmacokinetic models for volatile anaes-
thesia.
Mapleson described the blood flows and body tissues analogously to an
electrical circuit, where the tissue compartments are represented by capacitors
and the blood vessels by resistances, illustrated in Figure 2.1(a), (Mapleson,
1962, 1963, 1964a,b). The derived compartmental physiologically based model
was further tested and validated for halothane uptake in a dog by Allott et al.
(1976).
Eger described the uptake of the anaesthetic agent by a hydraulic model,
where different tissue groups are characterized by tanks of different diameters
and connected to one central tank, which represents the alveolar gas, and
is illustrated in Figure 2.1(b), (Cromwell et al., 1971; Eger, 1974; Eger and
Guadagni, 1963).
Based on the work of Mapleson, Zwart et al. and Smith et al. derived an
eight compartmental physiologically based model for the uptake of halothane,
(Smith et al., 1972; Zwart et al., 1972). Goldberg et al. applied this model
for closed loop anaesthesia of halothane, (Goldberg et al., 1978). Fiserova-
Bergerova et al. extended the model by adding additional tissue groups, i.e.
subcutaneous and inner adipose tissue, the liver and additional anaesthetic
agents, i.e. isoflurane, enflurane and methoxyflurane, (Fiserova-Bergerova,
1992; Fiserova-Bergerova and Holaday, 1979; Fiserova-Bergerova et al., 1974,
1980). Also Lerou et al. extended the Mapleson model to a 14 compartment
model for teaching and research purposes describing the simultaneous uptake
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of isoflurane, nitrous oxide and oxygen, which was then validated with clinical
data, (Lerou and Booij, 2001a,b, 2002; Lerou et al., 1991a,b, 2002; Vermeulen
et al., 1995).
Eger’s hydraulic model was further extended by Carpenter et al. (1986) to
a five compartmental mammillary model connected by one central compart-
ment, Figure 2.1(b). This approach was further applied and extended by
Yasuda et al. for uptake of desflurane, isoflurane and halothane, (Yasuda
et al., 1991a,b).
Kety was the pioneer towards characterisation of individualised drug uptake
depending on (i) drug solubilities or partition coefficients in the tissues and
(ii) the physiological variables such as the cardiac output, (Kety, 1950, 1951).
The description of one compartment itself in either the mammillary model
or the physiological based model can be described by complex interactions and
flows between e.g. blood cells, plasma, intestinal fluid, a rapid interactive pool,
and a slow interactive pool, illustrated in Figure 2.1(c). Bischoff (1975) gives
a comprehensive summary of physiologically based pharmacokinetic models.
Furthermore the concept of a flow-limited and/or a diffusion-limited model can
be applied to describe the uptake and distribution within one compartment,
(Thompson and Beard, 2011). Given a fast drug diffusion in the capillaries
from blood to tissue, in most approaches the compartments are assumed to
be flow-limited. In the perfusion-limited approximation the uptake of the tis-
sues is restricted by the permeability of the membranes separating blood and
tissue, (Bischoff, 1975, 1986).
2.2. Pharmacodynamic Modelling
The individualized characterisation of the pharmacodynamics, which link the
drug concentration to the drug effect, is more challenging because of higher
inter- and intra-patient variability, (Mertens and Vuyk, 1998).
To determine the hypnotic depth, anaesthetists commonly apply the Min-
imum Alveolar Concentration (MAC) as a guideline. MAC is defined as the
concentration required to prevent movement in response to surgical incision
in 50% of the patients. During general anaesthesia conventionally 1.3 MAC is
the target value, which assures sufficient anaesthesia in 90% of the patients,
(Eger et al., 1965). The resulting cumulative probability curve is shown in
Figure 2.2, (Krieger et al., 2012).
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Figure 2.2.: Population distribution of MAC for sufficient hypnosis with 95%
confidence interval. The gray dot denotes 1 MAC for 50% and the
black dot denotes 1.3 MAC for 90% of the population.
Figure 2.2 highlights the challenge of identifying the individual patient’s
sensitivity and anaesthetic state to avoid awareness or overdosing.
Already by definition the guideline for dosing of volatile anaesthetic agents
during anaesthesia is based on probability. This highlights the challenge of
identifying the individual patient’s sensitivity and consecutively the hypnotic
depth to avoid awareness or overdosing. Parameters influencing the individual
patient’s sensitivity are for example the age. Studies by Brunner et al. (1994)
investigated the correlation of MAC with patient characteristics or analgesics
administered simultaneously during anaesthesia. Mapleson (1996) and Eger
(2001) found that MAC decreases with age and that elderly patients are more
sensitive to anaesthetics. Furthermore the patient’s sensitivity towards the
anaesthetic agent changes depending on surgical stimulation and simultane-
ously administered drugs during anaesthesia, such as muscle relaxants and
analgesics, (Glass et al., 1997; Rosow, 1997). Recent advances investigate the
pharmacogenomic variability as an indicator of individual patient’s sensitivity
to anaesthetic agents, (Searle and Hopkins, 2009). The challenge is to include
the entire pharmacodynamic variability, which is estimated to vary up to 400%
by Mertens and Vuyk (1998), in the model. This task might be very complex
if not impossible.
2.3. Applications
Applications of mathematical models for drug delivery systems lie in the area
of patient simulators or mannequins for training of nurses, medical students
or anaesthetists and in on-line computation of the current drug concentrations
and effect during surgery.
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2.3.1. Patient Simulators and Simulation Tools for Teaching
and Training
The idea of using computer programs to simulate and predict the uptake of
the anaesthetic agent originates from the work of Tanner et al. (1986).
Training and teaching with patient simulators and mannequins is becoming
more common in modern medical education. One of the most advanced patient
simulators on the market is the CAE Healthcare© HPS® (CAE Healthcare,
2013). This patient simulator shows all vital functions and inhales and ex-
hales oxygen and anaesthetic agents according to a mathematical model, (Van
Meurs, 2011).
Several software tools for training are available, the most well known tool
is Gas Man®(MMSI, 2006), a computer tool for teaching, simulating and
experimenting with anaesthesia uptake and distribution.
2.3.2. On-line Monitoring and Prediction
The SmartPilot View by Dra¨ger (Herbst, 2010) or the Navigator Applications
Suite software by GE Healthcare (2013) are software tools that enable a fre-
quently updated state of the patient calculated based on drug infusions and
boluses and the measured variables e.g. the exhaled and inhaled gases and the
vital functions. The aim of these tools is to provide the anaesthetist with a
decision support. The anaesthetist can follow the moving state of the patient
in a 2D graph and see the future states for the given infusions and inhalations,
(Gru¨nberg, 2009).

3. Model for Volatile Anaesthesia
The first and essential step for any model predictive control design is the
derivation and validation of a model that is describing the system’s behaviour
accurately. The physiologically based model for the uptake, distribution and
effect of volatile anaesthetic agents presented in this section is based on the
work published in Krieger et al. (2013) and our previous work in Krieger et al.
(2011, 2012).
In this thesis the physiologically based pharmacokinetic modelling approach
is applied to describe the pharmacokinetics (PK) and address patient variabil-
ity by including patient-specific characteristics in the mathematical descrip-
tion, (Hall et al., 2012). The variability of the PK uncertainty is included
analogously to Fiserova-Bergerova (1992), where all volumes for blood tissue
and gas compartments are assigned specific to the individual patient’s weight,
height and age. By including these factors the aim is to reduce significantly
the variability in the PK, which is estimated to be around 60-80%, (Mertens
and Vuyk, 1998).
The challenge is to find the balance between a too complex but reasonably
simple model with respect to application in model predictive control and still
aim for the required detail, (Tanner, 1982).
3.1. Pharmacokinetics
The physiologically based compartmental model for volatile anaesthetics, Fig-
ure 3.1(a), is based on Eger’s compartmental model for volatile anaesthesia,
where the tissues with similar properties are lumped together resulting in three
body compartments representing the Vessel Rich Group (VRG), the Muscle
Group (M) and the Adipose Tissue (F), (Eger, 1974). Each body compart-
ment is further divided into an ideally mixed blood and ideally mixed tissue
part. This approach is based on a model for cancer chemotherapeutic drugs
first presented by Bischoff (1986). The gas, blood and tissue volumes are
individually adjusted to the weight, height, gender and age of the patient.
A detailed list of all variables and their units can be found in the notation
lists in the beginning of this thesis.
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The compartments are described assuming a flow-limited formulation. Hence,
the diffusion through the capillary vessel walls is assumed to be rapid and the
mass transfer of the drug into the tissue is restricted by the perfusion of the
compartment. This approximation is not fundamental to the physiological
pharmacokinetic approach, but commonly used due to the lack of sufficient
physiological information of e.g. membrane permeabilities, diffusion coeffi-
cients and tissue surfaces, (Bischoff, 1986). No inter-tissue diffusion between
the compartments e.g. from the VRG to the adipose tissue is included, (Zwart
et al., 1972). This implies that mass exchange only occurs through the blood
vessels. The transport time and the pulsatile character of the blood flow are
neglected, because the equilibration times are large compared to the cardiac
cycle, (Zwart et al., 1972). All fluxes leaving a gas, blood or tissue compart-
ment are in equilibrium with the compartment.
(a) Patient body.
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(b) Fluxes in the lungs.
Figure 3.1.: Structure of the physiologically based patient model.
The uptake of the anaesthetic agent is determined by two factors: the ven-
tilation of air through the lungs and the perfusion of blood through the lungs.
The ventilation is given by the product of the respiratory frequency fR and
the tidal volume VT . Only a part of the total minute ventilation V˙ , usually
two thirds, take part in the gas exchange in the lungs and reach the alveoli.
This alveolar ventilation V˙A is given by the total ventilation V˙ less the dead
space ventilation V˙D:
V˙A = V˙ − V˙D = fR(VT − VD) (3.1)
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Here fR and VT are set by the anaesthetic machine and the anaesthetist,
respectively. Analogously to (3.1) the alveolar volume VA is determined by
the lung volume VL less the dead space volume VD.
VA = VL − VD (3.2)
The applied mass balances and assumptions, the fluxes of gas and blood in
the lungs are shown in Figure 3.1(b).
The input variable of the model, to be optimised by the controller, is the
concentration of the inhaled volatile anaesthetic agent CI , routinely set by
the anaesthetist.
To map the respiratory cycle and the changing gas concentration in the
lungs, the concentration in the alveoli just after inspiration CAI is given in
(3.3) analogous to the Bohr equation for carbon dioxide, (Miller et al., 2010),
where the amount of inhaled anaesthetic gas is ideally mixed with the gas left
in the lungs after expiration. This equation aims to represent the time-varying
process of inspiration and expiration by a time invariant equation.
CAI (VA + VT ) = CI VT +CE VA (3.3)
The concentration during expiration is given by the assumption of an equilib-
rium between the end-tidal expired concentration CE and the mixed venous
blood concentration Cv¯. The concentrations are linked via the blood gas par-
tition coefficient λ, (Eger, 1974).
CE = Cv¯
λ
(3.4)
The anaesthetic uptake takes place in the alveoli of the lungs alongside with
the uptake of oxygen and the removal of carbon dioxide. The driving force
for all fluxes is the concentration difference between the mixed venous blood
and the arterial blood, (Miller et al., 2010). Additionally, the amount of gas
in the lungs and in the pulmonary capillaries, which are perfusing the alveoli,
is determined by the cardiac output Q˙. A part of the total cardiac output,
the shunt flow Q˙s, does not reach the alveoli and therefore is excluded from
the gas exchange, see Figure 3.1(b). This results in the following equation for
the uptake of the volatile anaesthetic in the lungs
uL = (Q˙ − Q˙s) (λCAI −Cv¯) (3.5)
with the blood gas partition coefficient λ. The concentration in the arterial
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blood Ca is determined by a mass balance of inlet and outlet fluxes indicated
in Figure 3.1(b) by the dashed line and uL in (3.5).
CaQ˙ = Cv¯Q˙ + uL (3.6)
The mixed venous blood concentration is given by an average of all blood
concentrations in the compartments multiplied with the perfusion of the re-
spective compartment. To account for the venous shunt, diversion of blood
from the artery directly to the vein, the last term in (3.7) is added.
Cv¯ =∑
i
rQ˙,iCb,i + (1 −∑
i
rQ˙,i)Ca (3.7)
The tissue compartments in Figure 3.1(a) are further divided into blood and
tissue sub-compartments, shown in Figure 3.2.
Blood
Tissue
Vb,i Cb,i
Vt,i Ct,i
Qi Qi
Figure 3.2.: Structure of one tissue compartment.
The concentrations of the anaesthetic agent in the individual compartments
are given by mass balances for each blood and tissue compartment.
Vb,i
dCb,i
dt
= Q˙i(Ca −Cb,i) − ut,i , i = V RG,M,F (3.8)
Vt,i
dCt,i
dt
= ut,i , i =M,F (3.9)
The mass balance of VRG tissue includes an additional term for the metabolism
of the anaesthetic agent in the liver mliv, where Q˙liv describes the perfusion
of the liver, (Saltzman, 2001).
Vt,V RG
dCt,V RG
dt
= ut,V RG − Q˙liv Ct,V RGmliv (3.10)
The driving force of the anaesthetic uptake by the tissue ut,i in each com-
partment is the difference of the concentration in the tissue at equilibrium for
the given concentration in the blood Cb,i and the actual concentration in the
tissue Ct,i, (Eger, 1974; Enderle et al., 2005). The partition coefficients λi
relate the concentrations in the tissue Ct,i to the concentrations in the blood
Cb,i at equilibrium. Analogously to (3.5) the uptake of the tissue in the body
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compartments is described in (3.11).
ut,i = Q˙i(λiCb,i −Ct,i) (3.11)
The perfusion of each compartment Q˙i is given by the cardiac output Q˙ and
the ratio of the cardiac output rQ˙,i perfusing the compartment.
Q˙i = rQ˙,i ⋅ Q˙ (3.12)
Similarly, the parameter rVb,i describes the ratio of the total blood volume
Vb in compartment i and rV,i to the ratio of total body tissue volume V ,
respectively.
Vt,i = rV,i ⋅ V (3.13)
Vb,i = rVb,i ⋅ Vb (3.14)
3.2. Individualised Pharmacokinetics
In the following sections the PK variables and parameters in (3.1) - (3.14) are
given as functions of the patient’s physiology, i.e. age, weight, height and
gender, to account for patient-variability.
3.2.1. Lumped Tissue Compartments
The volumes of the body compartments are given as a part of the total body
volume. The mass of the adipose tissue is a function of the Body Mass Index
(BMI), age and gender of the patient, (Deurenberg et al., 1991). The per-
centage of the body mass of VRG and the Vessel Poor Group (VPG) are not
primarily depending on the BMI of the patient. Thus, they are assigned as
a percentage of the ideal body weight for a person with the patient’s height,
BMI = 22 [kg/m2] for both genders, (Lemmens et al., 2006). The ideal body
weight for a patient with height h is given in (3.15).
mideal = 22 ⋅ h2 with BMI = m [kg](h [m])2 (3.15)
The body mass, which is neither allocated to the adipose tissue, nor to VPG
or VRG, is assigned to the muscle group. The mass and volume of VPG
is calculated to determine the volume of the muscle group and not further
considered in the mathematical model, as the perfusion and anaesthetic uptake
of the VPG tissue is negligible for short term anaesthesia. The equations for
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the patient-specific tissue compartment mass are given in Table 3.1.
Table 3.1.: Calculation of patient-specific tissue mass.
Parameter Description Equation Unit Ref
mF Adipose
mass
(1.2 BMI−10.8 gender◊+
0.23 age − 5.4) ⋅ 0.01m kg Deurenberget al. (1991)
mV PG VPG mass 0.2 ⋅mideal kg Miller et al.
(2010)
mV RG VRG mass 0.1 ⋅mideal kg Miller et al.
(2010)
mM Muscle mass m−mF −mV PG −mV RG kg◊female: gender = 0, male: gender = 1
The volume of the compartments is determined by the average density of
the tissue of the compartment, (Heymsfield et al., 2005).
Vi = mi
ρi
(3.16)
3.2.2. Blood Volume
The blood volume is adapted to height h in [cm], weight m in [kg] and gender
of the patient published by Nadler et al. (1962), where f denotes a female and
m a male patient.
VB,f = 0.3561h3 + 0.03308m + 0.1833 (3.17a)
VB,m = 0.3669h3 + 0.03219m + 0.6041 (3.17b)
3.2.3. Cardiac Output
The cardiac output Q˙ in [L/min] as a function of the patient’s BMI, age and
gender is adapted from Stelfox et al. (2006); gender = 1 for a female patient
and gender = 0 for a male patient.
Q˙ = 5.84 + 0.08 BMI − 0.03 age − 0.62 gender (3.18)
Further coefficients for additional predictors such as simultaneously admin-
istered agents or the patient’s health state and be found in Stelfox et al. (2006).
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3.2.4. Lung Volume
The ventilated lung volume less the dead space determines the distribution
volume of the inspired anaesthetic in (3.2) and (3.3). On average, men have
larger lungs than women. During anaesthesia the ventilated lung volume re-
duces to approximately the functional residual capacity, altered by atelectasis
and anaesthetic side-effects. The patient-specific functional residual capacity
as a function of the BMI in litres is given by Pelosi et al. (1998).
VL = 11.97 exp(−0.096 BMI) + 0.46 (3.19)
3.3. Pharmacodynamics
Pharmacodynamics (PD) describe the link of the concentration of the anaes-
thetic agent to the effect of the drug. In a common modelling approach for
drugs with response delays a hypothetical effect-compartment, which describes
the mathematical link between the plasma concentrations and drug effects, is
added to the equation system. This hypothetical compartment is solely ap-
plied to describe the delay of the drug action by a mathematical equation and
does not contribute towards the pharmacokinetics of the drug. Therefore it is
not reflected in the pharmacokinetic equations, (Mager et al., 2003; Sheiner
et al., 1979). The effect-site concentration Ce in this hypothetical effect site
compartment is given as follows:
dCe
dt
= ke0 (Ca −Ce) (3.20)
Here, Ca denotes the concentration in the arterial blood calculated in (3.6),
Ce denotes the effect site concentration and ke0 denotes the first order rate
constant describing the delay of drug action.
The hypnotic effect, which is of interest in our case, is measured by the BIS
and calculated as a function of the concentration in the effect site compart-
ment, Ce, by the Hill equation. Originally, the Hill equation was first used
by Hill (1910) to describe the equilibrium relationship between the partial
pressure of oxygen in the blood and the saturation of haemoglobin. Now it is
known as a standard equation in pharmacology, (Goutelle et al., 2008).
BIS = BIS0 + (BISmax −BIS0) Cγe
Cγ50 +Cγe , (3.21)
where C50 is the concentration triggering 50% of the total effect or the potency
of the drug and γ the slope of the Hill equation in (3.21). BIS0 describes the
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initial effect at no anaesthetic concentration BIS0 = 100 and BISmax describes
the maximum effect BISmax = 0. The three PD parameters ke0, C50 and γ
are individual patient characteristics and might change during the course of
anaesthesia triggered by e.g. surgical stimulation or drug interaction.
3.4. Individual Patient Variables and Parameters
In this section the range of the PK and PD variables and parameters as a func-
tion of the patient’s physiology, i.e. age, weight, height and gender, are cal-
culated. Here, variables refer to values that might change over time, whereas
parameters are constant. All PK and PD variables and parameters, their
nominal values and range are summarised in Table 3.2.
In the presented model the individual PK variables are the cardiac output,
the shunt flow, the distribution of the cardiac output on the compartments, the
lung shunt, the dead space volume and the lung volume. All variables are likely
to change during the course of anaesthesia as a function of the concentration
of the anaesthetic agent, other simultaneously administered drugs or surgical
stimulation.
The deviation for the cardiac output Q˙ is calculated for patients with a
body weight of 45-100 kg, body height of 1.50-1.90 m, age of 18-90 years and
both genders in (3.18).
The shunt flow Q˙s results from a 0% to 30% shunt of the cardiac output
increased by atelectasis, which is often occurring during anaesthesia, (Miller
et al., 2010).
For the distribution of the cardiac output on the different compartments no
deviation was found in the open literature. The baroreflex is still active during
light to moderate anaesthesia and aims to provide the essential, well perfused
organs, with oxygen. Therefore the ratio of the vessel rich group is assumed to
increase slightly, whereas the perfusion of the fat and muscle group decreases,
(Miller et al., 2010).
The dead space is altered from a normal value of VD=150 mL ≈ 30%VT to
VD=600 mL ≈ 60%VT caused by atelectasis, (Miller et al., 2010).
The deviation in the lung volumes is given by (3.19) for patients with a BMI
in the range of 20 to 40 covered in the study by Pelosi et al. (1998).
The PK parameters are the partition coefficients, the tissue volumes and
the blood volumes, which are constant during the entire course of anaesthesia.
The deviation for the blood gas partition coefficient λ and the tissue parti-
tion coefficients λi were summarised and published by Eger et al. (2002) from
different sources.
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The tissue volumes are calculated for patients with a body weight of 45-
100 kg, a body height of 1.50-1.90 m and both genders applying the equations
in Table 3.1. The blood volumes are calculated based on the assumptions that
the blood volume Vb is proportional to the perfusion of the compartment and
that 60% of the total blood volume is distributed on the systematic tissue,
(Saltzman, 2001).
Vb,i = 0.6Vb rQ˙,i (3.22)
The PD parameters are ke0, C50 and γ in (3.20) and (3.21). The variation
in the PD parameters was published in a study by Gentilini et al. (2001). The
values at the boundary of the estimation problem were excluded. In Gentilini
et al. (2001) the effect site concentration Ce is linked to the alveolar gas con-
centration, whereas in the model presented here the effect site concentration
is linked to the arterial blood concentration (3.20). To ensure consistency be-
tween these two models, the value of C50,A found by Gentilini et al. (2001) is
multiplied with λ to scale Ce from alveolar to arterial concentration, analo-
gously to (3.4).
C50,a = λC50,A (3.23)
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Table 3.2.: Range and nominal values for PK and PD parameters and vari-
ables; partition coefficients at 37oC for isoflurane.
Symbol Nominal
value
Deviation Unit Ref.
PK
λ 1.4 1.38-1.46 - Eger et al. (2002)
λF 50 43.84-55.8 - Eger et al. (2002)
λM 2.57 1.44-3.19 - Eger et al. (2002)
λV RG 1.65 1.45-1.86 - Eger et al. (2002)
Q˙ 5 000 3 520-7 300 mL/min Stelfox et al. (2006)
Q˙s 150 0-1 500 mL/min Miller et al. (2010)
rQ˙,F 0.054 0.045-0.054 - Eger (1974)
rQ˙,M 0.181 0.1-0.181 - Eger (1974)
rQ˙,V RG 0.75 0.75-0.765 - Eger (1974)
Vb 4 900 2 875-6 339 mL Nadler et al. (1962)
Vb,F 160 69-205 mL Eger (1974),
Nadler et al. (1962)
Vb,M 410 276-688 mL Eger (1974),
Nadler et al. (1962)
Vb,V RG 1495 1 293-2 910 mL Eger (1974),
Nadler et al. (1962)
VD 150 150-600 mL Miller et al. (2010)
VL 2 000 770-2 200 mL Pelosi et al. (1998)
Vt,F 14 500 4 563-4 5300 mL Eger (1974)
Vt,M 33 000 20 010-55 789 mL Eger (1974)
Vt,V RG 6 000 4 950-7 942 mL Eger (1974)
PD
C50,A 0.7478 0.2959-1.094 vol% Gentilini et al. (2001)
γ 1.534 0.2-2.351 - Gentilini et al. (2001)
ke0 0.3853 0.0248-2.895 1/min Gentilini et al. (2001)
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3.5. Concluding Remarks
The presented mathematical model for volatile anaesthesia provides an update
with modifications of the standardly applied models for control of volatile
anaesthesia, (Eger, 1974; Yasuda et al., 1991a; Zwart et al., 1972). The uptake
of the tissue compartments and in the lungs is described separately by explicit
equations and the PK parameters and variables are calculated based on the
patient’s physiology.
In the next section this model is analysed and the most influential variables
and parameters are identified.

4. Model Analysis
This section presents an extensive analysis of parameters and variables in the
physiologically based model described in Chapter 3. The aim is to identify the
uncertainty the controller has to cope with. This uncertainty is originated by
inter-patient variability. In a consecutive step the model is analysed towards
its most influential parameters and variables. The methods used to gain an
in-depth understanding of the model are global sensitivity analysis, parameter
estimation and parameter correlation. The results presented in this chapter
were published in Krieger et al. (2013).
4.1. Uncertainty by Inter-patient Variability
The outcome of this section is to identify the imposed uncertainty, which is, or
may be, originated by patient variability with respect to the output of interest,
the BIS.
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Figure 4.1.: BIS for PK (left) and PD (right) variability summarised in Ta-
ble 3.2; dash dotted line: BIS nominal PKs; solid line: BIS indi-
vidualised PKs for Patient 1; black dots: measured BIS.
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For this purpose, separate simulations for the full range of PK and PD
variability in Table 3.2 were performed for isoflurane based anaesthesia with
set time-varying inputs for fR, VT and CI . Details about the patient and the
inputs are given in Section 5.1, Patient 1: Figure 5.1, Table 5.1. The resulting
envelopes of uncertainty with respect to the BIS by PK and PD variability
are shown in Figure 4.1. By comparison of the envelopes of uncertainty in
Figure 4.1 the uncertainty introduced by PD variability is identified more
profound than the uncertainty introduced by PK variability. More specifically,
the maximum deviation from the BIS for nominal PK values is 25%, whereas
the maximum deviation of the BIS including PD variability and PK values
adjusted to Patient 1 is 56%.
Additionally, the improved model prediction, given individual pharmacoki-
netics, is illustrated in Figure 4.1. For this purpose, the model is simulated
for nominal patient variables given in Table 3.2, denoted by the dash dotted
line, and for individualised pharmacokinetics presented in Section 3.2, de-
noted by the solid line, in Figure 4.1. A comparison of the two simulation
results with the measurements, denoted by the black dots, shows a significant
improvement of the prediction achieved by calculating the PK variables and
parameters based on the patient’s physiology.
Normally during anaesthesia the anaesthetist modifies the inhaled concen-
tration according to the obtained measurements in order to maintain adequate
anaesthesia. The high deviation in the variables clearly support the need for
additional information about the patient in order to assure adequate hypnosis.
4.2. Global Sensitivity Analysis
In this section the relative influence of the uncertain PK and PD parameters
and variables on the measurable outputs is investigated via global sensitivity
analysis. For volatile anaesthesia the measurable outputs are the end-tidal
volatile anaesthetic concentration CE and the BIS. The results of the global
sensitivity analysis are several sensitivity indices between 0 and 1, with 0 being
non-influential. The sensitivity index (SI) represents the relative influence of
the parameter or variable on the output of interest at the given time; the sum
of all sensitivity indices for the applied Sobol method converges to one. The
sensitivity indices of the PK and PD parameters and variables presented in
this section were calculated with the GUI-HDMR software, (Ziehn and Tomlin,
2009). To perform the analysis all PK and PD parameters and variables were
varied between their bounds; the resulting output and the scaled input from 0
to 1 for a large number of sampling points are required by the GUI-HDMR soft-
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ware. The method applied in the GUI-HDMR software uses random sampling
high dimensional model representation (RS-HDMR) to construct an expression
for the output as a function of the parameters with orthogonal polynomials.
This expression accounts for up to second order interactions and corresponds
to the ANOVA decomposition truncated to second order. From the coefficients
of the representation the SI is derived. The sensitivity indices are calculated
based on partial variances, which themselves are calculated by the approxima-
tion of the model by orthonormal polynomials. For further details on how the
sensitivity indices are derived consult: Li et al. (2002) and Ziehn and Tomlin
(2009).
In total, four sensitivity analyses for the PK and PD variables and param-
eters with 26 000 sampling points were performed. The samples were created
by simulating the model in gPROMS via the gOMATLAB interface.
In Case 1 the influence of the PK variables and parameters on the end-tidal
concentration CE is investigated, because the PK variables and parameters de-
scribe the distribution of the anaesthetic agent in the human body. In Case 2
the influence of the PK variables and parameters on the BIS is investigated.
The PK variables and parameters influence the BIS via their effect on the
arterial concentration linked to the effect site concentration and to the BIS,
(3.20) and (3.21). In Case 3 the influence of the PD parameters, which charac-
terise the link of the arterial blood concentration to the BIS is investigated. In
Case 4 all PK and PD variables and parameters were analysed with respect to
the BIS. For Case 1 and Case 2 all PD parameters were fixed at their nominal
values, while in Case 3 the PK parameters were fixed at their nominal val-
ues. In Case 4 all PK and PD variables and parameters were varied between
their lower and upper bounds in Table 3.2. The four cases are summarised in
Table 4.1.
Table 4.1.: Cases of the sensitivity analyses.
Fixed Varied Output
Case 1 PD PK CE
Case 2 PD PK BIS
Case 3 PK PD BIS
Case 4 - PK, PD BIS
For the sensitivity analysis the inspired concentration, the respiratory fre-
quency and the tidal volume, were kept constant: CI = 1.1 vol%, fR = 12 min
−1,
VT = 500 mL. All concentrations were initialised with zero. The sensitivity
indices of all PK and PD variables and parameters for Case 1-Case 4 are sum-
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marised in Table 4.2.
Table 4.2.: Relative Sobol’ SIs using GUI-HDMR (Ziehn and Tomlin, 2009) of
Case 1-Case 4 in Table 4.1 after 5 min and 20 min.
Case 1: CE Case 2: BIS Case 4: BIS
Variable 5 min 20 min 5 min 20 min 5 min 20 min
PK
λ 0.0 0.0 0.0094 0.0134 0.0018 0.0031
λF 0.0 0.0 0.0 0.0 0.0 0.0
λM 0.0104 0.0259 0.0030 0.0127 0.0005 0.0028
λV RG 0.0312 0.0144 0.0097 0.0101 0.0020 0.0020
Q˙ 0.1812 0.1428 0.0462 0.0919 0.0101 0.0187
Q˙s 0.1665 0.1763 0.2362 0.2134 0.0400 0.0457
rQ˙,F 0.0017 0.0034 0.0005 0.0016 0.0002 0.0005
rQ˙,M 0.0568 0.0937 0.0175 0.0489 0.0033 0.0111
rQ˙,V RG 0.0002 0.0004 0.0002 0.0006 0.0 0.0
Vb,F 0.0024 0.0027 0.0034 0.0023 0.0 0.0
Vb,M 0.0078 0.0085 0.0006 0.0001 0.0 0.0
Vb,V RG 0.0132 0.0043 0.0060 0.0030 0.0010 0.0006
VD 0.0055 0.0054 0.0076 0.0065 0.0013 0.0013
VL 0.4595 0.4766 0.6539 0.5663 0.1101 0.1215
Vt,F 0.0003 0.0003 0.0001 0.0001 0.0 0.0
Vt,M 0.0043 0.0067 0.0267 0.0265 0.0001 0.0003
Vt,V RG 0.0753 0.0559 0.0162 0.0369 0.0038 0.0071
PD
Case 3: BIS Case 4: BIS
C50 - - 0.4241 0.7709 0.3124 0.5698
γ - - 0.2840 0.1224 0.2813 0.0851
ke0 - - 0.2809 0.0815 0.1947 0.0638
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The time-varying PK and PD sensitivity indices of all cases defined in Ta-
ble 4.1 are shown in Figure 4.2. The PK variables and parameters with an
average SI<0.01 were excluded for the purpose of clarity.
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Figure 4.2.: Time-varying relative Sobol’ SIs of Case 1-Case 4. The three bot-
tom plots denote a zoomed in scope of Case 1, Case 2 and Case 4.
In Case 1 the distribution volume of the anaesthetic agent, the lung volume
VL, has the highest SI with respect to the end-tidal concentration CE during
the entire course of anaesthesia. The PK variables with the next highest sen-
sitivity indices are the cardiac output and the shunt flow. Hence, as expected,
the ventilation and perfusion have the highest influence on the uptake of the
volatile anaesthetic agent.
For Case 2, lung volume, cardiac output and lung shunt are identified, anal-
ogously to Case 1, as the crucial variables with respect to the BIS, and hence
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the arterial blood concentration to which the BIS is linked via the effect site
concentration Ce in (3.20).
Case 3 shows that at the beginning the sensitivity indices of the PD param-
eters γ and ke0 are approximately identical, while C50 has the highest index
and hence the highest influence on the BIS. Under the assumption of a con-
stant inspired concentration, the sensitivity of C50 increases to approximately
90% after 60 min. The results of Case 3 in Figure 4.2 are in accordance with
the formulation of equations (3.20) and (3.21). Only C50 relates the BIS to
a specific effect site concentration. The parameter γ changes the slope of the
Hill equation and defines the necessary change in the effect site concentration
to achieve the desired change in the BIS. The PD parameter ke0 determines
how fast the BIS is responding to a change in the inputs and determines the
delay of the effect. Neither γ nor ke0 are affecting the steady state BIS value.
In Case 4, the PD parameters are identified to have the highest sensitivity
during the beginning of anaesthesia, whereas for a longer course of anaesthesia,
especially the lung volume’s SI is increasing.
From a physiological aspect and as a conclusion of the sensitivity analy-
sis of Case 1 and Case 2, the cardiac output and the shunt flow determine
the anaesthetic uptake in the circulation and the lung volume determines the
anaesthetic uptake in the ventilation. All other PK parameters have a consid-
erably lower SI and can be regarded as negligible compared to the lung volume,
the cardiac output and the lung shunt flow. Case 3 and Case 4 illustrate that
C50 is the most important parameter in order to obtain the correct depth of
anaesthesia for the individual patient.
4.3. Variability Analysis
In this section the influence of the individual parameters and variables on the
outputs is further investigated. The sensitivity analysis in Section 4.2 gives a
measure of the relative influence of each parameter on the output. This does
not include whether a higher or lower value of the parameter or variable of
interest is increasing or decreasing the output. The variability analysis further
expands the understanding of the model and the influence of each parameter
and variable. For an understanding of the actual physical influence of the
PK and PD variables and parameters, it was investigated whether an increase
in the PK or PD variable or parameter increases or decreases the output y,
here CE and/or BIS. For this study the calculated nominal outputs ynom of
CE and BIS were compared to the outputs of CE and BIS when changing the
respective PK or PD variable or parameter one by one to the upper ymax and
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the lower bound ymin, while keeping all other variables and parameters at their
nominal values.
P%,i = ymax,i − ymin,i
ynom
. (4.1)
The percentage of change P%,i of CE and BIS are obtained with gPROMS,
(PSE, 2011) and the gOMATLAB interface. The results are summarised in
Table 4.3.
Table 4.3.: P%,i of CE and BIS after 5, 20 and 60 min; CI = 1.1 vol%, fR =12
and VT =500 mL.
CE BIS
Variable 5 min 20 min 60 min 5 min 20 min 60 min
PK
λ 0.0 0.0 0.0 -2.01 -3.60 -4.12
λF -0.08 -0.10 -0.16 0.01 0.04 0.08
λM -9.59 -11.27 -13.97 1.46 4.29 6.73
λV RG -12.24 -5.03 -0.81 1.96 2.34 0.43
Q˙ 28.89 17.34 8.97 -4.11 -7.71 -4.46
Q˙s -26.10 -21.25 -17.11 9.43 14.38 13.25
rQ˙,F -2.70 -2.86 -3.11 0.42 1.11 1.52
rQ˙,M -18.42 -17.67 -12.64 2.90 6.75 6.19
rQ˙,V RG -0.44 0.10 0.01 0.14 -0.04 0.00
Vb,F 0.0 0.0 0.00 0.0 0.0 0.0
Vb,M -0.26 -0.12 -0.10 0.06 0.05 0.05
Vb,V RG -8.26 -3.06 -0.47 1.50 1.44 0.25
VD 5.39 4.09 3.14 -1.92 -2.56 -2.24
VL -77.81 -50.87 -36.32 25.79 27.63 23.06
Vt,F -0.06 -0.24 -0.88 0.01 0.08 0.41
Vt,M -1.07 -4.02 -11.35 0.12 1.39 5.41
Vt,V RG -19.24 -10.59 -1.61 2.59 4.84 0.87
PD
C50 - - - 28.06 49.25 56.19
γ - - - 27.71 14.34 4.55
ke0 - - - -37.69 -52.55 -23.98
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The results in Table 4.3 and the sign of P% show how an increase or decrease
of a parameter or variable generates a lower or higher anaesthetic uptake. The
BIS is a function of the arterial concentration Ca. Hence, for an increased up-
take the BIS is increasing, see VL. Simultaneously, the end-tidal concentration,
CE , is decreasing given a higher anaesthetic uptake.
The simulations clearly confirm the results obtained by the previous sensi-
tivity analysis, as the PK and PD variables with the highest SI also show the
highest absolute value on the outputs in terms of P%,i.
4.4. Parameter Estimation and Correlation
The envelope of BIS uncertainty by PK variability is significantly smaller than
the envelope of uncertainty by PD variability in Figure 4.1. This motivates an
attempt to estimate the PD parameters in order to capture the uncertainty
as a consequence of PK variability. This statement is investigated for the
envelope of PK variability in Figure 4.1.
The parameter estimation problem is evaluated by the correlation matrix
C of the estimated parameters. An entry in the off-diagonal elements of the
correlation matrix C close to one (∣Cij ∣ ≈ 1) indicates a high correlation of
the corresponding parameters i and j, whereas an entry of zero (∣Cij ∣ ≈ 0)
indicates no correlation. The entries of the correlation matrix are calculated
based on the variance-covariance matrix V . The variance of a parameter is
given on the diagonal (Vii) and the covariance of two parameters i and j on
the off-diagonal elements (Vij). Further details can be found in the gPROMS
user guide, (PSE, 2011).
Cij = Vij√
ViiVjj
, i ≠ j (4.2a)
Cii = 1 (4.2b)
During the following analysis the upper bound of the envelope shown in Fig-
ure 4.1 is referred to as PKu, while the lower bound is referred to as PKl. The
evaluation of the quality of the estimates is performed for both cases.
The correlation matrix of VL and the three PD parameters obtained using
gPROMS (PSE, 2011) is given in Table 4.4.
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Table 4.4.: Correlation matrix C of C50, γ, ke0 and VL for the parameter esti-
mation problem PKu and PKu; PKu above diagonal and PKl below
diagonal.
C50 γ ke0 VL
C50 1 0.644 -0.691 -0.993
γ 0.662 1 -0.312 -0.713
ke0 -0.753 -0.368 1 0.697
VL -0.992 -0.663 0.791 1
The results show that VL and the PD parameters are highly correlated, in
particular C50 and VL, where CC50,VL≈ - 0.99. As a consequence C50 and VL
cannot be estimated independently or, for this case, the uncertainty imposed
by variability in the PK variables and parameters can be captured and a
sufficiently accurate BIS can be reproduced by the adjustment of the PD
parameters only. This statement is investigated for PKl and PKu; this time
only estimating the PD parameters.
The correlation matrix of the PD parameters for PKl and PKu for all PD
parameters obtained using gPROMS (PSE, 2011) are summarised in Table 4.5.
Table 4.5.: Correlation matrix of the PD parameters, entries for PKu above
diagonal and PKl below diagonal.
C50 γ ke0
C50 1 -0.759 -0.0033
γ 0.0563 1 0.383
ke0 0.431 0.348 1
Here, the PD parameters γ and C50 show minor correlation originated by
the formulation of (3.21).
All values of the PD parameters are obtained solving a maximum likelihood
parameter estimation problem with gPROMS and lie within their respective
bounds in Table 3.2, (Bard, 1974; PSE, 2011).
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Table 4.6.: Estimated PD parameters for PKl and PKu.
PKl PKu
C50,A 0.6177 0.8962
γ 1.4458 1.6369
ke0 0.4308 0.2978
The results of the fit are shown in Figure 4.3. Here PKl and PKu denote
the upper and lower bound of the PK uncertainty envelope and PKl,est and
PKu,est the BIS for the estimated PD parameters given in Table 4.6.
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Figure 4.3.: BIS output for estimated PD parameters in Table 4.5 captur-
ing PK variability Figure 4.1. PKl and PKu denote the upper
and lower bound of the PK uncertainty envelope and PKl,est and
PKu,est the output for values of the PD parameters given in Ta-
ble 4.5.
This analysis shows that via PD parameter estimation it is possible to cap-
ture the uncertainty introduced by potential PK variability. Hence, the PD
parameters C50, ke0 and γ are sufficient to predict the BIS under uncertainty
in the PK and PD variables and parameters. This statement is further inves-
tigated for a set of clinical patient data in the next section.
4.5. Concluding Remarks
This chapter provides a framework for a structured analysis of the parameters
and variables that influence the measurable outputs, which results in an in-
depth understanding of the model.
The PD parameters are clearly identified as the parameters with the highest
variability and highest influence on the BIS.
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In the next section the model is validated with clinical data for isoflurane
and desflurane based volatile anaesthesia.

5. Model Validation
A simulation study for isoflurane based anaesthesia of three patients and for
desflurane based anaesthesia of eight patients is presented in this section. The
anonymised data were provided by the Department of Medical Informatics
in Anesthesiology and Intensive Care Medicine of the University of Gießen
in Germany. Isoflurane and desflurane concentrations were measured with
an anaesthesia ventilator (Primus, Draeger medical) and BIS was measured
by patient monitoring (IntelliVue MP70, Phillips). The data were recorded
on-line with an anaesthesia information management system (NarkoData®,
IMESO GmbH). Anaesthesia was induced by propofol and maintained with
isoflurane and desflurane respectively, simultaneously administered analgesics
were fentanyl and/or sufentanil. Cisatracurium was used for muscle relaxation.
The results for isoflurane based anaesthesia were published in Krieger et al.
(2013).
5.1. Isoflurane Based Anaesthesia
In this section measured data of isoflurane based anaesthesia are compared
to the simulated data obtained by the model presented in Chapter 3 and
simulated in gPROMS. Anaesthesia was induced with propofol and maintained
with isoflurane. The details and drug doses are summarised in Table 5.1.
The individual PD parameters for each of the three patients were obtained
by a parameter estimation problem. For comparison, the expected BIS for the
nominal PD parameters in Table 3.2 were computed. All simulation results
and measurements are shown in Figure 5.1.
The characteristics of the three patients for isoflurane based anaesthesia and
the values of the estimated PD parameters are also summarised in Table 5.1.
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Table 5.1.: Patients’ characteristics; calculated values of the lung volume
(3.19) and cardiac output (3.18) and estimated PD parameters;
details of the surgery and simultaneously administered drugs.
Patient 1 Patient 2 Patient 3 Units
age 61 65 66 yrs
BMI 31.5 14.5 26.0 kg/m2
h 1.69 1.7 1.63 m
m 90 42 69 kg
gender m m f m/f
VL 1041 2200
† 1449 mL
Q˙ 6530 5052 5317 mL/min
C50,A 0.3981 0.3600 0.5660 vol %
γ 0.4920 0.6169 1.9974 -
ke0 1.117 0.0248
‡ 0.3832 1/min
ASA status 2 2 3
surgery urology urology general surg.
Propofol▲ 200 120 200 mg
Fentanyl◊ 1 0.5 1 mg
Sufentanyl◊ - 55 - µg
Cisatracurium◊ 22 28 30 mg
†VL at upper bound;
‡estimate at lower bound.
▲Dose of 1% solution propofol for induction of anaesthesia.
◊Sum of single doses during entire course of surgery.
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Figure 5.1.: Inspired and expired isoflurane concentrations and BIS for three
patients. The measured data points are denoted with (meas),
the BIS for individually estimated PD parameters is denoted with
(est) and the expected BIS for the PD nominal values is denoted
with (def).
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The simulation results of the end-tidal concentration CE for Patient 1 and
Patient 3 are in good accordance with the measurements CE (meas). Hence,
the PK model shows a good fit of the data. However, for Patient 2 the model
is not predicting the measured end-tidal concentration as close. This might
be related to the underweight of the patient, BMI=14.5, for which the PK
parameters have to be modified with additional knowledge about the patients
health state. The expected BIS for the PD nominal variables, BIS (def),
show the best match with the measured BIS for Patient 1. Especially for
Patient 3 a considerable off-set between the measurement and the predicted
BIS is observed. For individually estimated PD parameters the predicted BIS
is in good accordance with the measurement for all three patients.
The prediction of the end-tidal concentration CE by adjusting the PK vari-
ables and parameters according to the pharmacokinetic model presented in
3.1 shows good results. However, the PD parameters need to be estimated to
fit the measured data.
5.2. Desflurane Based Anaesthesia
In this section measured data of eight patients undergoing desflurane based
anaesthesia are compared to the simulated data obtained by the model pre-
sented in Chapter 3 and simulated in gPROMS. Anaesthesia was induced with
propofol and maintained with desflurane. The characteristics of the eight pa-
tients are summarised in Table 5.4.
For the simulations the solubilities of desflurane published by Eger et al.
(2002) were used. All other variables were calculated as described in Chapter 3
Table 3.2.
Table 5.2.: Solubilities of desflurane in tissue and blood, (Eger et al., 2002).
Solubility Value
λ 0.45
λF 29
λM 1.73
λV RG 1.3
The individual PD parameters for each of the eight patients were obtained by
a parameter estimation problem. PD values for desflurane based anaesthesia
were reported as a function of the end-tidal anaesthetic concentration, Ca ≙
CE in (3.20), by Rehberg et al. (1999) and Ro¨pcke et al. (2001). Ro¨pcke
Chapter 5 69
et al. (2001) found different PD parameters during surgical stimulation of
the patient and during times without surgical stimulation. The range of the
PD parameters for desflurane based anaesthesia for the parameter estimation
problem are taken from Rehberg et al. (1999).
Table 5.3.: PD parameter range for desflurane, (Rehberg et al., 1999).
min max
C50,A 1 8
γ 0.5 2
ke0 0.2 1.6
All simulation results and measurements are shown in Figures 5.2 - 5.3.
Table 5.4.: Patients’ characteristics; calculated values of the lung volume
(3.19) and cardiac output (3.18) and estimated PD parameters;
P denotes Patient.
P 4 P 5 P 6 P 7 P 8 P 9 P 10 P 11 Units
age 55 27 83 54 64 68 32 76 yrs
BMI 28.3 23.5 23.7 21.4 31.0 27.4 21.9 31.7 kg/m2
h 1.88 1.75 1.79 1.81 1.74 1.76 1.85 1.83 m
m 100 72 76 70 94 85 75 106 kg
gender m f m m m m m m m/f
VL 1252 1713 1688 1999 1068 1319 1920 1033 mL
Q˙ 6680 6479 5437 6100 6652 6215 6808 6345 mL/min
C50,A 3.60 1.57 1.56 1.12 2.16 1.31 2.24 2.19 vol %
γ 0.50‡ 0.90 0.50‡ 0.50‡ 0.77 0.50‡ 0.50‡ 0.50‡ -
ke0 0.20
‡ 0.20‡ 0.25 0.20‡ 0.28 0.20‡ 0.36 1.60† -
ASA 1 1 3 3 3 2 1 2 -
†Estimate at upper bound; ‡Estimate at lower bound.
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Figure 5.2.: Inspired and expired desflurane concentrations and BIS for Patient
5-7. The measured data points are denoted with (meas), the BIS
for individually estimated PD parameters is denoted with (est).
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Figure 5.3.: Inspired and expired desflurane concentrations and BIS for Patient
8-11. The measured data points are denoted with (meas), the BIS
for individually estimated PD parameters is denoted with (est).
72 Chapter 5
The prediction of the end-tidal concentration CE by adjusting the PK vari-
ables and parameters according to the pharmacokinetic model presented in
3.1 shows very good accordance with the measurements of the end-tidal con-
centration measurements CE (meas) for Patient 5, Patient 6, Patient 8 and
Patient 11. Also the simulation results of the other patients show a cor-
rect tendency of the measured data. The prediction of the BIS is in good
accordance for individually estimating the PD parameters even though the
estimated values lie at the boundary of the estimation problem, Table 5.4.
This study confirms that C50 is the parameter with the highest influence, not
at the boundary for any patient.
The maintenance of the depth of anaesthesia for Patient 4 in Figure 5.2,
even though the administration of desflurane is stopped, is ensured by an
extra bolus dose of 500 mg 1% solution propofol.
The mismatch of the prediction of the BIS for Patient 10 in Figure 5.3 is
also explained by an extra dose of 150 mg 1% solution of propofol to ensure
a safe depth of anaesthesia. This decision was taken by the anaesthetist to
ensure a safe anaesthesia as a response to the rising BIS measurement.
5.3. Concluding Remarks
The high inter-patient variability of the PD parameters, already observed in
this study for three patients undergoing isoflurane based anaesthesia, is further
confirmed. This shows the need for on-line estimation of the PD parameters.
The PD parameters γ and ke0 do not seem to be essential for the parameter
estimation problem, as they are at their respective bounds, primarily for the
desflurane study. This might be due to the lack of data during induction of
anaesthesia. However, the estimation of C50 is sufficient to obtain a good
match with the clinical data. Therefore, C50 is further recommended to be
estimated on-line.
The strategy of choice to ensure sufficient and correct prediction of the
depth of anaesthesia through the mathematical model is an on-line parameter
estimation (Parker and Doyle, 2001) and is investigated in Chapter 10.
6. Simulation Results
In this chapter the capabilities of using the model presented in Chapter 3
as a teaching tool for the distribution and uptake of volatile anaesthetics are
demonstrated. By applying the model, additional in-sights of drug concentra-
tions in tissues and blood pools that are not accessible by measurement are
possible.
In Figure 6.1 all tissue and blood concentrations for Patient 1 in Table 5.1,
Figure 5.1 are depicted.
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Figure 6.1.: Isoflurane tissue and blood concentrations for Patient 1, Table 5.1,
Figure 5.1.
Figure 6.1 shows that the concentrations in the tissues are considerably
higher than the concentrations in the blood pools, due to the higher capacity of
accumulation and a higher solubility of the volatile anaesthetic agent, (Miller
et al., 2010).
In Figures 6.2 - 6.4 the blood and tissue concentrations of the desflurane
study of Patient 4 in Table 5.4, Figure 5.2 are shown. Figure 6.2 shows that
the concentrations of desflurane are much lower compared to the inspired
concentrations. This is related to the lower solubilities of desflurane in the
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tissues and blood, Table 5.2.
0 50 100 150 200 250
0
1
2
3
4
5
6
7
8
9
time [min]
C 
[v
ol 
%
]
 
 C
I
C
E
C
a
C
v
Cb,VRG
C
t,VRG
Cb,M
C
t,M
Cb,F
C
t,F
Figure 6.2.: Desflurane tissue and blood concentrations for Patient 4, Ta-
ble 5.4, Figure 5.2.
Further a simulation is performed to investigate the influence of body weight
on the induction and wake-up times. As an example a simulation is performed
where Patient 4 is assumed to be obese, 180kg, and underweight, 55kg and
the influence of this change in body weight distribution is shown in Figure 6.3
and Figure 6.4 respectively.
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Figure 6.3.: Desflurane tissue and blood concentrations for obese Patient 4,
Table 5.4, Figure 5.2.
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Figure 6.4.: Desflurane tissue and blood concentrations for underweight Pa-
tient 4, Table 5.4, Figure 5.2.
A comparison of Figure 6.3 and Figure 6.4 shows that the concentration in
the adipose tissue Ct,F in Figure 6.3 is increasing rapidly. This is explained
by the high solubility of desflurane in fat and the comparatively small volume
of the compartment.
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Figure 6.5.: Wake up phase of anaesthesia, u - underweight, o - obese, Ca
arterial concentration, CE end-tidal concentration.
After administration of desflurane the arterial concentration, Ca, and the
end-tidal concentration, CE , of both patients are similar. This is illustrated in
Figure 6.5. This results contradicts the assumption of longer wake-up times
in obese patients, because of anaesthetic accumulation in the fatty tissue and
reintroduction into the circulatory system, when the arterial concentration
of the anaesthetic drops after anaesthetic administration. Clinical studies by
Cork et al. (1981) confirm the simulation results. Cork et al. also found similar
wake-up times for normal and obese patients. This is further confirmed by the
global sensitivity analysis, Section 4.2 Table 4.2. The low SI of Vt,F indicates
that the volume of the fatty tissue has a relatively low impact on the BIS and
CE .
6.1. Concluding Remarks
The derived model shows additional features to existing teaching and simu-
lation tools to contribute to better understanding of anaesthesia and enables
predictions of the drug concentrations in the various tissue parts of the patient.
Part II:
Optimisation and Model
Predictive Control
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Objective and Summary
The objective of Part II is to design a control strategy based on the system
model derived in Part I, which is able to handle the uncertainty through inter-
patient variability identified in Part I.
Model Analyis
Control
Closed-Loop
Control System
Validation
Robust Control
Strategies
(Chapter 9 and 10)
Validation and testing of the
designed control strategy
with ‘real’ patient models.
(Chapter 9 and 10)
Off-set free control strate-
gies adjusting to the indi-
vidual patient’s dynamics.
Figure 6.6.: Control framework and contributions presented in Part II.
The extensive review and analysis of the system model in Part I, Figure 1.4,
help to thoroughly design and validate a control strategy for optimal and
safe closed-loop control under uncertainty. The contributions of this part are
illustrated in Figure 6.6 and are summarised as follows:
I) Design of a closed-loop control strategy for robust off-set free control of
the hypnotic depth of volatile anaesthesia.▶ Model linearisation.⪧ Algebraic compensation of the non-linear Hill equation.⪧ Piece-wise affine linearisation of the non-linear Hill equation.▶ State estimation by the ‘perfect’ observer and the Kalman filter.▶ Model predictive control under uncertainty.⪧ Control strategy able to adjust to the patient’s dynamics.⪧ On-line parameter estimation of the parameter with the highest
sensitivity: C50 as identified in Part I.
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⪧ Disturbance rejection for an intravenous anaesthesia linear pa-
rameter varying (LPV) system1.
II) Validated closed-loop control strategy for patients undergoing isoflurane
based anaesthesia presented in Part I - Chapter 5.▶ Testing of nominal, open-loop, mp-MPC control strategies for ‘real’
patients.▶ Testing and validation of the control strategies with robust set-point
tracking for ‘real’ patients.▶ Testing of on-line parameter estimation for ‘real’ patients.
1This work, in collaboration with Chang et al. (2013b), was submitted for publication and
is summarised in Appendix D.
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7. Model Predictive Control of
Anaesthesia
In the operating theatre the anaesthetist faces the task of providing sufficient
hypnosis, analgesia and muscle relaxation, while maintaining the vital func-
tions of the patient. The idea of supporting the anaesthetist with decisions on
drug infusion rates and/or to directly automate the amount of infused drug has
been an active research topic since the 1950s, (Chilcoat, 1980). Particularly
in critical situations, model predictive control design is believed to contribute
to safe and optimal anaesthesia, (Hemmerling, 2009).
Before surgery the reference point and the constraints are individually ad-
justed by the anaesthetist to the patient and type of surgery. Given this
information, the control action can be modified according to the patient’s
characteristics and the duration and requirements of surgery. Here the states
of the patient are determined via monitoring devices, whereas non-measurable
states are estimated based on the available measurements. Foreseen and un-
foreseen disturbances such as surgical stimulation might occur during surgery,
which the control strategy has to cope with and reject successfully. Dur-
ing anaesthesia a combination of drugs is administered to assure anaesthesia,
amnesia, muscle relaxation, analgesia and maintain the vital functions. The
combinations of different drugs, e.g. anaesthetics, analgesics and muscle re-
laxants, is big and often a personal choice of the anaesthetists based on their
experience and preference.
The automation of intravenous control of anaesthesia is more advanced,
because the plasma concentration of the intravenous anaesthetic is not directly
measurable and hence drove the search for (i) a measurement device for the
hypnotic depth and (ii) a reliable model to predict the plasma concentration.
An open-loop control example, which is common in clinical practise, for
intravenous anaesthesia, usually using propofol, is target controlled infusion
(TCI). Here, the drug infusion is based on model predictions of the plasma
concentration in the patient’s blood. The hypnotic depth is measured by
the BIS or other measurement devices. Recent advances in total intravenous
anaesthesia (TIVA) are listed in Table 7.1. TIVA is not as common as volatile
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anaesthesia.
Volatile anaesthesia is preferred by most anaesthetists, because of the stan-
dardly available measurement of the end-tidal concentration, which is directly
linked to the arterial drug concentration and the drug concentration in the
brain. Therefore the end-tidal concentration is commonly used as a guideline
to determine the hypnotic depth of the patient, cp. Section 2.2 Figure 2.2.
The automatic drug administration of volatile anaesthetic agents was first
considered by Westenskow et al. (1986) and tested in a dog by Zbinden et al.
(1986). Advances on the control of volatile anaesthesia are given in Table 7.2.
Mansour and Linkens (1989), Behbehani and Cross (1991) and Yu et al. (1992)
used automatic drug infusion devices to maintain the hemodynamic state of
the patient, e.g. the cardiac output or the blood pressure. Since then re-
searchers understood the benefit of automatic control of anaesthesia. In Table
7.3 studies that report a better performance of automatic control compared
to manual control are summarised. Due to the multiple-input multiple-output
character of the system, where the inputs are the various drug infusions and
the outputs are the anaesthetic states of the patient and/or the vital functions,
different model predictive control (MPC) methods such as explicit MPC, gen-
eral predictive control or fuzzy logic control were applied to the system.
The control of the end-tidal concentration is commercially available in the
Zeus® anaesthesia machine. Here the research interest is motivated by patient
safety, reduction of the pollution of the operating theatre with the anaesthetic
agent and reduction of consumption of the anaesthetic agents. A summary is
given in Table 7.4.
Table 7.1.: Closed-loop intravenous anaesthesia in the operating theatre.
Reference Summary
Hemmerling et al. (2013) McSleepy platform: propofol, remifentanil,
rocuronium.
West et al. (2013) closed-loop propofol anaesthesia in children.
Hemmerling et al. (2010) Significantly better control for the closed-loop
propofol administration for 40 patients com-
pared to manual control, measured by BIS.
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Table 7.2.: Closed-loop control of depth of volatile anaesthesia in the operating
theatre.
Reference Summary
Reboso et al. (2012) PI controller for closed-loop propofol infusion
measured by BIS, feasible and safe for a clin-
ical study of 12 patients.
Liu et al. (2006) closed-loop control with propofol outperforms
manual control, assessment of depth of hyp-
nosis by BIS, 163 patients.
Gentilini et al. (2001) Isoflurane based anaesthesia feedback by BIS
for 20 patients.
Lockwood (1998) Closed-loop PID control with isoflurane and
enflurane.
Table 7.3.: Manual vs. closed-loop control.
Reference Summary
Locher et al. (2004),
Stadler (2003)
Performance for closed-loop isoflurane control
in favour for automatic control (23 patients).
Morley et al. (2000) No significant difference between closed-loop
and manual control of (i) propofol/alfentanil
and of (ii) isoflurane anaesthesia.
Table 7.4.: Closed-loop control of end-tidal volatile anaesthetic concentration.
Reference Summary
Singaravelu and Barclay
(2013)
Improved anaesthetic consumption for desflu-
rane and sevoflurane for closed-loop control of
end-tidal concentration.
Lortat-Jacob et al. (2009) Desflurane and oxygen end-tidal concentra-
tion control resulting in economical more ben-
eficial anaesthesia with Zeus® anaesthesia
machine.
Struys et al. (2005) Good performance of desflurane and sevoflu-
rane target end-tidal concentration in a test
lung with Zeus® anaesthesia machine.
Sieber et al. (2000) closed-loop control of end-tidal concentration,
performing better than manual control for
isoflurane anaesthesia.

8. Closed-loop Explicit Model
Predictive Control
8.1. Model Predictive Control
Model predictive control (MPC) uses a process model to compute the op-
timal input sequence by minimising an objective function, while respecting
constraints on the control inputs, the outputs and the states of the system.
The control of volatile anaesthesia system is described as a reference tracking
problem. Here, the objective is to find the optimal input trajectory to steer
the BIS, measuring the anaesthetic depth, to a target reference point. At each
time step the optimal control input u corresponding to the inhaled concen-
tration CI for the patient is calculated. An illustrative figure of the control
objective is given in Figure 8.1. Further notation is given in the nomenclature
in the beginning of this thesis.
t t+1 t+2 t+M t+M+1 t+N-1 t+N
Control horizon M
Output horizon N
PresentPast Future
yR
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t+1
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t+Ny
R
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ut+1ut
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yt+Nyt+M
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Figure 8.1.: Illustration of MPC, dotted line: MPC system output (y), dashed
line: real system output (ym), light grey solid line: output refer-
ence point (yR), grey solid line: control input (u).
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The optimal control trajectory u at each point is calculated as the optimal
solution of an objective function. Although the optimal sequence of u for
the entire prediction horizon N is computed, only the control input u0 at the
current time point is implemented and at the next time point the objective
function (8.1) is solved repeatedly.
min
u
J = x′NPxN + N−1∑
k=1 x′kQxk +
N∑
k=1(yk − yRk )′QR(yk − yRk )
+M−1∑
k=0 u′kRuk +
M−1∑
k=0 ∆u′kR1∆uk
s.t. xk+1 = Axk +Buk
yk = Cxk
xmin ≤ x1, . . . xN ≤ xmax
umin ≤ u0, . . . , uM−1 ≤ umax
ymin ≤ y1, . . . , yN ≤ ymax
∆umin ≤ u−1 − u0, . . . , uM−2 − uM−1 ≤ ∆umax
(8.1)
N output horizon
M control horizon, with M ≤ N
P weight matrix on the final states
Q weight matrix on the states
QR weight matrix on reference tracking error
R weight matrix on control input u
R1 weight matrix on change in control input
A,B,C linear state space system matrices
x states of the system, (Cb,i, Ct,i)
y system output, (CE , BIS)
yR reference point
ymk measured system output
u control input, (CI)
∆u step change in control input, (∆CI)
The application of MPC is restricted by an on-line optimisation step re-
quired to obtain the optimal control inputs at every time point for the given
states and reference trajectory, (Mayne et al., 2006; Sui et al., 2008). For a
complex model with multiple inputs and outputs, and constraints, a fast and
expensive on-line computer is required. In the worst case the optimisation can-
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not be solved in the available time. Explicit MPC overcomes this drawback of
the need for a real-time optimiser, (Bemporad et al., 2002), and furthermore
allows extensive testing of the control action for different scenarios, because
all possible control trajectories are pre-computed off-line.
To obtain an explicit MPC solution, the objective function is formulated
as a multi-parametric quadratic programming (mp-QP) problem, where the
objective function in (8.1) is formulated as a function of the parameters θ
and the optimisation variables U = [u0, u1, . . . , uM−1], which are the control
inputs for the entire control horizon. In the parameter vector all dependent
variables of the objective function are included θ = [x0, u−1, yR], where x0 are
the states of the system at the start of the horizons, ut−1 is the previous control
input, to obtain ∆u0, and y
R is the constant reference trajectory for the entire
prediction horizon N.
This results in the following formulation of the objective function (8.1) as
an mp-QP:
min
U
J(θ) =1
2
U ′HU + θ′FU + 1
2
θ′Y θ (8.2a)
s.t. GU ≤W +Eθ (8.2b)
with θ = [x0, ut−1, yR] and Ut = [ut, ut+1, . . . , ut+M−1]. A detailed description of
the reformulation of the MPC objective function as an mp-QP problem with
equality and inequality constraints is given in Appendix A.
The mp-QP problem in (8.2) can now be solved with multi-parametric pro-
gramming techniques, which are implemented in the POP toolbox for MAT-
LAB, (Bemporad et al., 2002; ParOS, 2004). The optimal solution of the
mp-QP problem (8.2) Ut is obtained as a set of continuous piece-wise affine
functions of the parameters θt which are known or measured at the current
time point t and therefore are fixed in the objective function.
Ut =
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
K1θt + c1 if H1θt ≤ b1,⋮
KnCθt + cnC if HnCRθt ≤ bnCR ,
(8.3)
where Ut = Kiθt + ci for i ∈ {1, . . . , nCR} is the optimal solution in the critical
region Hiθt ≤ bi. Here nCR denotes the number of critical regions of the
solution of the mp-QP problem (8.2).
Applying multi-parametric MPC, the expensive on-line computation of the
optimal control function is bypassed (on-line optimisation via off-line optimi-
sation) and the previously computed control law can be implemented low-cost
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on a chip (MPC-on-a-chip), citepPistikopoulos2009. Hence, the optimal con-
trol law is retrievable immediately through simple function evaluations.
Advantages of mp-MPC for drug delivery systems for anaesthesia are:
▶ Hard constraints on states (drug concentrations) and inputs (drug infu-
sion).
▶ Advance testing with respect to high safety standards.
8.2. Robust Control
One of the key challenges for the design of drug delivery systems for anaesthesia
is the high inter-patient and intra-patient variability, which introduces a high
degree of uncertainty into the system. Therefore the control design should be
robust against implying uncertainty and tested for the uncertain system.
In brief, robust control can be defined as the solution of an optimal tra-
jectory of the system under the presence of uncertainty and/or disturbances,
which guarantees constraint satisfaction for all admissible values of uncer-
tainty, and optimally steers the system to the target reference point, (Bempo-
rad and Morari, 1999; Rawlings and Mayne, 2009).
The uncertainty can originate from model-mismatch, non-captured hidden
process dynamics and/or input or output disturbances, (Muske and Badgwell,
2002).
The uncertain system can be described by the linear time invariant (LTI)
system where wk represents the bounded disturbance analogously to noise
entering the system, (Bemporad and Morari, 1999):
xk+1 = Axk +Buk +Gwk
yk = Cxk + Fwk (8.4)
The bounded disturbance wk belongs to a compact polyhedral set wk ∈W ⇔{wLk ≤ wk ≤ wUk }, i = 1, . . . ,w, (Sakizlis et al., 2004a). In an alternative
approach, uncertainty is included by considering polyhedral uncertainty on
the system matrices described as follows:
xk+1 = Akxk +Bkuk
yk = Cxk (8.5)
where [Ak Bk] ∈ Ω and Ω = conv{[A1 B1], . . . , [AM BM ]} is the convex hull
of [Ai Bi], (Bemporad and Morari, 1999).
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Robust control strategies obtain a feasible and optimal solution with respect
to bounded uncertainty of the types described in (8.4) and (8.5).
An open-loop solution is the formulation of a min max optimisation problem,
where the optimal value for u is obtained under the assumption of maximal
uncertainty in wk. This solution is equivalent to the optimisation of the worst-
case scenario, which is often not realistic for the actual system and might
lead to an over-conservative controller, (Kouramas et al., 2008; Sakizlis et al.,
2004a,b).
An extended approach is a closed-loop parametric controller, where the past
uncertainty is included at each step in the computation of the optimal con-
trol law, (Bemporad et al., 2003; Kerrigan and Maciejowski, 2004; Kouramas
et al., 2008; Manthanwar et al., 2005; Pistikopoulos et al., 2009; Sakizlis et al.,
2004a).
In the algorithm presented by Kouramas et al. feasibility and constraint
satisfaction is assured for bounded polytopic uncertainty in the system matri-
ces A and B (8.5) and the objective function is derived based on the nominal
values of the state space system A0 and B0, (Kouramas et al., 2011, 2013;
Panos et al., 2010; Pistikopoulos et al., 2009). These algorithms guarantee
feasibility and constraint satisfaction under the given polytopic or additive
uncertainty.
Robust reference tracking algorithms are required for systems with steady
state disturbances that might otherwise lead to a persisting off-set. Sakizlis
et al. presented an mp-MPC controller with integral action for off-set free
control by adding an integral state defined as follows, (Sakizlis et al., 2002,
2004a),
xq,k+1 = xq,k + (yR − yk)´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶
error
, ∀k = 1, . . . ,N (8.6)
and added penalties in the objective function (8.1)
min
u
J = x′q,NPqxq,N + N−1∑
k=1 x′q,kQqxq,k. (8.7)
To incorporate the disturbance model explicitly in the controller’s dynamics
the input and state disturbance can be determined by a Kalman filter, (Badg-
well and Muske, 2002; Maeder and Morari, 2010; Maeder et al., 2009; Muske
and Badgwell, 2002; Sakizlis et al., 2004b). In this approach the system is
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augmented with an integrating disturbance d
⎡⎢⎢⎢⎢⎣xk+1dk+1
⎤⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎣A Bd0 I
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣xkdk
⎤⎥⎥⎥⎥⎦ +
⎡⎢⎢⎢⎢⎣B0
⎤⎥⎥⎥⎥⎦uk +wk
yk = [C Cd] ⎡⎢⎢⎢⎢⎣xkdk
⎤⎥⎥⎥⎥⎦ + vk
(8.8)
and a Kalman filter is applied to estimate the states and the disturbances of
the augmented system (8.8). The choice of the matrices Bd and Cd determines
whether the augmented system is observable and depends on the known pro-
cess and the disturbance model. The most common choice is Bd ∈ Rn×nd = 0
and Cd = I ∈ Rnd×nd , where n is the dimension of the state vector and nd the
dimension of added disturbance vector, (Pannocchia and Bemporad, 2007).
An additional condition is that the state space system can reach the target
reference point. For an LTI system of the form in (8.4) the system can reach
a target reference point under any disturbance when A¯, defined in (8.9), has
full rank, (Pannocchia and Bemporad, 2007; Pannocchia and Rawlings, 2003):
rank
⎡⎢⎢⎢⎢⎣I −A −BHC 0
⎤⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶
A¯
= n + nd, (8.9)
If condition (8.9) holds and the system is detectable, off-set free tracking can
be obtained, (Rawlings and Mayne, 2009, p.49), and the closed-loop aug-
mented system, under the condition that no constraints are active, reaches
the reference point without off-set
Hys = yR, (8.10)
where ys denotes the system output at steady state, (Rawlings and Mayne,
2009, p.49).
For the system of anaesthesia, a control strategy considering polytopic un-
certainty on the system matrices A and B (8.5) or assuming the maximum
possible disturbance (8.4) will result in an off-set, when the optimal control
trajectory is computed based on the nominal system. Hence, robust, off-set
free tracking algorithms should be applied for the control design of anaesthesia.
An alternative for a robust control strategy, describing the system as a
linear time varying system (LPV), is evaluated in Appendix D, (Chang et al.,
2013a,b).
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8.3. State Estimation
State feedback control strategies are relying on full state information. For the
anaesthesia system not all states, which are the drug concentrations in the
compartmental model, can be measured directly. Therefore a state estimator
is required to determine the unmeasured states based on the input, the system
model and the available measurements.
8.3.1. ‘Perfect’ Observer
A straightforward and obvious open-loop control approach to determine the
system’s states is via a copy of the system, where the input of the system uk
is known.
xˆk+1 = Axˆk +Buk
yˆk = Cxˆk (8.11)
However, this is only applicable if the system matrices are known with a high
accuracy, the initial states are known and no disturbances are present or the
system is fully observable, hence all states can be measured.
On the contrary, one has to consider that the state feedback controller is
derived based on these system dynamics.
The advantages and disadvantages of the ‘perfect’ observer are summarised
as follows:
4 Simple implementation.
MPC is based on the same model, therefore there is no risk of infeasibil-
ity.
8 No compensation for model uncertainty and/or external disturbances.
8.3.2. Kalman Filter
The state estimation of the linear Kalman filter gives the unconstrained state
estimation by minimising the error covariance. This is the optimal solution for
linear stochastic systems with independent zero mean Gaussian process noise
vk and measurement noise wk, (Kalman, 1960; Rawlings and Mayne, 2009).
xk+1 = Axk +Buk +wk
yk = Cxk + vk, (8.12)
where wk represents the process noise and vk the measurement noise with
covariance matrix Qˆ and Rˆ respectively. The solution of the state estimation
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problem is obtained in a predictor-corrector algorithm, (Rawlings and Mayne,
2009):
1) Time update:
State prediction:
xˆ−k = Axˆk−1 +Buk−1 (8.13)
Projection of the error covariance:
P−k = APk−1AT + Qˆ (8.14)
2) Measurement update:
Computation of the Kalman gain ∶
Kk = P−k CT (CP−k CT + Rˆ)−1 (8.15)
State estimate update:
xˆk = xˆ−k +Kk(yk −Cxˆ−k) (8.16)
Update of the error covariance:
Pk = (I −KkC)P−k (8.17)
The advantages and disadvantages of the Kalman filter are summarised as
follows:
4 Simple implementation, stable and optimal.
8 Not optimal for non-zero mean.
Unconstrained.
8.4. Concluding Remarks
Multi-parametric model predictive control (mp-MPC) techniques and formu-
lations will now be further investigated in the context of drug delivery systems
for anaesthesia. In the next section the control and state estimation strate-
gies, presented in this section, are combined to design and evaluate a control
strategy for volatile anaesthesia.
9. Control Design for Volatile
Anaesthesia
In this chapter the design and evaluation of the closed-loop control strategy
for volatile anaesthesia is presented. A schematic of the closed-loop control
structure is depicted in Figure 9.1.
Set point
selector
MPC Patient
BISR CI
State Estimator
PD
Ce
PK
Cb,i,Ct,i
CE
BIS
Cˆ
Figure 9.1.: Closed-loop control design for volatile anaesthesia.
The control objective is a fast onset and stable maintenance of the desired
depth of hypnosis measured by the BIS. In order to achieve this objective
the MPC manipulates the control input, the inspired concentration CI . The
feedback MPC calculates the optimal control strategy as a function of the
states of the system and the measured outputs.
The available measurements are the BIS and the end-tidal concentration
CE . Given these measurements and the control input CI , the state estimator
obtains the predicted states Cˆ of the system that are not measurable.
For control validation the patient model is simulated with different PK and
PD variables and parameters compared to the nominal values.
9.1. State Estimator
For the applied state feedback MPC design the optimal control law is obtained
as a function of the system’s states. This is indicated by the state estimator
block in Figure 9.1. For the control of volatile anaesthesia the two measurable
outputs are the end-tidal concentration, CE , and the BIS.
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For constant inputs, fR and VT , the system results in a linear state space
system, where the end-tidal concentration is the output,
Ck+1 = ACk +BCI,k
CE,k = CCk. (9.1)
The state vector C is of dimension n= 7:
C = [Ce CPK]′ = [Ce Cb,V RG Ct,V RG Cb,M Ct,M Cb,F Ct,F ]′ (9.2)
The state space vector C, (9.2), contains 6 pharmacokinetic states (CPK), i.e.
the concentrations in the blood and tissue compartments in the respective
compartments of the PK model and the effect site concentration, Ce, of the
PD model.
Because of the identified higher uncertainty in the pharmacodynamics than
in the pharmacokinetics the strategy of choice is to estimate the states based
on the measurement of the end-tidal concentration, CE , which is a PK vari-
able. The effect site concentration, Ce, cannot be estimated from the mea-
surement of the end-tidal concentration, CE , because the output related to the
effect site concentration is the BIS and not CE , see (3.20) and (3.21). This
can be concluded from the physiological understanding of the system and the
observability matrix O, (Rawlings and Mayne, 2009). The analysis of the ob-
servability matrix for the state space system (9.1) further confirms that an
estimation of the effect site concentration by the end-tidal concentration is
not possible, i.e.
O =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
C
CA⋮
CAn−1
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(9.3)
with the state space system matrices A and C, (9.1). Here n denotes the rank
of A in (9.5) for the system including all n= 7 states in (3.8)-(3.10), (3.20),
which are the 6 PK states, CPK and Ce. The rank of O is lower than n, i.e.
rank(O) = 6 < n = 7 (9.4)
Hence, only 6 states of the 7 states are observable based on the measurement
of CE . These are the 6 PK states: the blood and tissue concentrations in the
lumped body compartments, (3.8)-(3.10).
As a result the 6 states of the PK model, CPK, are estimated based on
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the end-tidal concentration, CE , with the linear state space model given as
follows:
CˆPKk+1 = A CˆPKk +BCI,k +wk (9.5)
CˆE,k = C CˆPKk + vk, (9.6)
The 6 PK states, CPK, are estimated by a Kalman filter, described in sec-
tion 8.3.2, with measurement noise covariance matrix Rˆ and process noise
covariance matrix Qˆ.
The effect site concentration, Ce, is estimated as a function of the estimated
arterial concentration, Cˆa, see Chapter 3, and given by combination of (3.1)-
(3.7) and (3.20):
Cˆa,k = (1 − Q˙s
Q˙
)(λ(CIVT + CˆE,kVA)
VA + VT ) − Q˙sQ˙ CˆE,k λ, (9.7)
Cˆe,k+1 = AeCˆe,k +BeCˆa,k (9.8)
where CˆE refers to the estimated end-tidal concentration obtained from (9.6)
and Ae and Be denote the discrete state space system matrices resulting from
(3.20).
An estimation of Cˆe based on the BIS measurement and all PD parameters
of the Hill equation, which would include, all three PD parameters, γ, C50
and ke0, is not performed due to the high uncertainty in the PD parameters
by inter- and intra-patient variability and the possibility of an inaccurate es-
timation. Hence the estimation of Ce is predicted to be more accurate based
on the PK concentration and only one of the PD parameters, i.e. ke0, by the
combination of (9.7) and (9.8).
9.2. Model Linearisation
Under the assumption of constant inputs for the respiratory frequency fR
and the tidal volume VT such as constant PK variables, the model equations
presented in Chapter 3 result in a linear system with the 7 states (9.2).
The only static non-linearity is introduced by the Hill equation (3.21), which
relates the linear PK model to the effect measured by the BIS. In this work we
only consider linear mp-MPC algorithms. The Hill equation is an algebraic
equation and therefore introduces a static non-linearity into the system. Two
options to compensate for the non-linearity are considered in this work.
I) Algebraic inverse of the Hill equation
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II) Linearised Hill equation
i) Linearisation at BIS reference point
ii) Set of piecewise affine functions
Both options and their advantages and disadvantages are discussed in this
section.
I) Algebraic Hill equation
The reference effect site concentration CRe is calculated by the inverse of the
Hill equation for the reference BISR, (Gentilini et al., 2001; Ionescu et al.,
2008; Nascu et al., 2012)
CRe = C50 ⎛⎜⎝ BIS
R −BIS0
BISmax −BISR⎞⎟⎠
1/γ
. (9.9)
The control design consisting of the mp-MPC controller, a state estimator,
the patient and the inverse Hill equation is depicted in Figure 9.2.
State Estimator
PK
Est.
Cˆe = f (Cˆa)
Controller
MPC
Patient
PK PD
inverse
Hill equation
BISR
CRe C
m
e
CI
CI
BISm
CE
CˆPK Cˆ
Cˆe
Figure 9.2.: Control design for algebraic inverse of the Hill equation.
This design requires robustification against the uncertainty in the PD pa-
rameters C50 and γ, which are parameters of the Hill equation (3.21) and (9.9).
For the proposed design of compensating the non-linearity by the inverse of the
Hill equation these parameters are not included in the control design where
they can be compensated by the disturbance rejection formulation in (8.8).
Hence, this design can only compensate uncertainty in the PD parameter ke0.
The advantages and disadvantages of the algebraic inverse of the Hill equa-
tion are summarised as follows:
4 Exact approximation of the Hill equation.
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8 Robustification strategy for inter-patient variability in C50 and γ.
II) Linearised Hill equation
The second design is a linearisation of the Hill equation at the desired reference
point. This control design is depicted in Figure 9.3.
State Estimator
PK
Est.
Cˆe = f (Cˆa)
Controller
MPC
Patient
PK PD
BISR
CI
CI
BISm
CE
CˆPK Cˆ
Cˆe
Figure 9.3.: Control design for linearised Hill equation.
The linearised Hill equation is given by
BIS∣BISlin = aBISlin Ce + bBISlin , (9.10)
where lin denotes the linearisation point. The linearisation constants for a
linearisation at BIS = 50 are:
aBIS50 = (BISmax −BIS0)⎛⎜⎝ γ4C50
⎞⎟⎠ (9.11a)
bBIS50 = BIS0 + (BISmax +BIS0)2 − aBIS50 C50 (9.11b)
i) Linearisation at reference point
The linearised Hill equation at the operating point of BIS = 50 was applied
by Gentilini et al. (2001) and Yelneedi et al. (2009). The visualised linearisa-
tion is shown in Figure 9.4 for nominal isoflurane PD parameters.
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Figure 9.4.: Linearised Hill equation at BIS = 50. The dot marks the lineari-
sation point.
However, this approach might not be accurate when the anaesthetist decides
another operating point e.g. BIS = 40 or BIS = 25 as in the case study for
desflurane in Section 5.2. Furthermore the intersection of the linearised Hill
equation and the y-axis does not coincide with the initial condition of the
patient during induction, where BIS = 100. Hence this strategy results in a
large off-set during induction of anaesthesia.
The advantages and disadvantages of the linearisation at a single reference
point are summarised as follows:
4 Good approximation at reference point.
Straight-forward implementation.
8 Large linearisation error outside of the linearisation region.
ii) Set of piecewise affine functions
A safer and more accurate linearisation procedure to achieve a smooth tran-
sition of the non-linearity for the full Hill equation is a set of piecewise linear
approximations, where the Hill equation is linearised at BIS = 60 and BIS = 30
and the controller is switching at the intersection points. The linearisation for
induction is obtained by a line through the points (BIS = 100, Ce = 0) and
(BIS = 60, Ce =Ce,BIS =60), Figure 9.5.
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Figure 9.5.: Piece-wise linearisation of the Hill equation. The dots mark the
intersection of the linearisation functions and the switching points
of the controllers respectively.
The advantages and disadvantages of the piecewise affine linearisation of
the Hill equation are summarised as follows:
4 Linearisation of the full parameter space.
Compensation of uncertainty in C50 and γ.
8 Implementation of controller switching to guarantee stability.
9.3. MPC
The MPC block in Figure 9.1 is based on the derived PK-PD in Chapter 3
for nominal patient parameters. The formulation of the linear MPC objective
function is given as follows, (8.1):
min
u
J = N∑
k=1(yk − yRk )′QR(yk − yRk ) +
M−1∑
k=0 (u′kRuk +∆u′kR1 ∆uk)
s.t. xk+1 = Axk +Buk
yk = Cxk
xmin ≤ xk ≤ xmax
ymin ≤ yk ≤ ymax
umin ≤ uk ≤ umax
∆umin ≤ uk−1 − uk ≤ ∆umax
(9.12)
The main objective of this reference tracking control problem is a fast onset
and a stable maintenance of the anaesthetic depth specified by the anaes-
thetist. Therefore the term with the highest weight in the objective function
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(9.12) is the weight matrix QR penalising the error between system output and
reference point. The inlet concentration u = CI is penalised with R, to min-
imise the amount of anaesthetic used. The change in the input ∆u ∶= ut−1 −ut
is penalised with R1. The states x, outputs y, inputs u and the change in
input ∆u are restricted by hard constraints, (9.12).
9.4. Case study: Controller Evaluation for
Isoflurane Based Anaesthesia
In this section the control designs described in the previous chapter are eval-
uated. To motivate for the need of an output feedback controller an open-
loop control design is included in the case study. The control strategies are
presented and compared regarding their performance for a reference point
change for a 60 min isoflurane based anaesthesia. The initial reference point is
BIS = 40 during the initial 30 min and BIS = 60 for the last 30 min. The MPC
is derived based on the model for the nominal patient described in Section 5.1,
MPC block in Figure 9.1.
The linear mp-MPC is evaluated applying
I) the algebraic inverse of the Hill equation or
II) a piecewise affine linear approximation of the Hill equation
in combination with either
i) the ‘perfect’ observer or
ii) the Kalman filter.
Performance measure
The performance error of the controller during induction and maintenance is
assessed by the root mean squared error (RSME) defined as follows:
E = 1
n
n∑
i=1
¿ÁÁÁÀ(ymi − yRi
yRi
)2, (9.13)
where yR refers to the reference output value and ym to the measured value.
This measure for the evaluation of the control strategy was chosen to include
a measure for oscillations.
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9.4.1. Motivational Example: Nominal mp-MPC
In this section the nominal controller, for both control designs, the algebraic
compensation of the Hill equation and the piecewise linear approximation of
the Hill equation, is evaluated. The perfect observer and the Kalman filter
are applied to obtain the state information of the system. Here, the imple-
mentation with the ‘perfect’ observer is equivalent to an open-loop control
design. The control designs are summarised in Table 9.1 and the MPC design
parameters in (9.12) are summarised in Table 9.2:
Table 9.1.: Control design (CD ) set-up.
MPC State Est PD
CD 1 mp-MPC ‘Perfect’ observer algebraic
CD 2 mp-MPC Kalman filter algebraic
CD 3 mp-MPC ‘Perfect’ observer linearised
CD 4 mp-MPC Kalman filter linearised
Table 9.2.: mp-MPC tuning parameters and specifications.
Variable Value Variable Value Unit
ts 0.1667 ≙ 10 sec ∆umax 0.5 vol %
N 6 ≙ 1 min ∆umin -0.5 vol %
M 3 ≙ 30 sec umax 4 vol %
QR 1000 umin 0 vol %
R 1 Ce,max 3.08 vol %
R1 1 Ce,min 0 vol %
Qˆ 0.3 BISmax 100 -
Rˆ 0.03 BISmin 0 -
The mp-MPC (9.12) is evaluated for the patients undergoing isoflurane
based anaesthesia. The designs CD 1-CD 4 are evaluated for the nominal pa-
tient and the three other patients of the clinical study for isoflurane. The
patient block in Figure 9.1 comprises of the model with individualised PK
and PD parameters and variables reported in Table 3.2 and Table 5.1. As a
motivational example for the need of a more advanced than open-loop control
strategy, the control performance for the nominal controller in line with the
‘perfect’ observer (CD 1 ) is shown for all patients in Figures 9.6 - 9.9. The
explicit solution CI by simple function evaluations of the first 6 critical regions
passed is given in Appendix B.
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Figure 9.6.: CI all patients.
The open-loop controller computes the optimal control law entirely based
on the obtained states by the state estimator. There is no output feedback
loop of the actual measurement of the patient. Therefore, an identical control
input for all four patients is computed, Figure 9.6.
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Figure 9.7.: CE all patients.
Figure 9.7 shows a significantly different end-tidal concentration CE for the
same inhaled concentration CI in Figure 9.6 for the four patients. This is a
result of different PK parameters of each patient, which determine a different
uptake and CE of the anaesthetic agent, cp. Table 4.3.
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Figure 9.8.: Measured BIS of all patients.
Figure 9.8 shows the BIS of all four patients. The open-loop, nominal MPC
obtains a good control performance for the nominal patient (Pn) only. The
other patients, in particular Patient 3 (P3), show a significant off-set from the
target BIS.
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Figure 9.9.: Ce all patients.
The results in Figure 9.9 show a satisfactory performance of CD 1 only for
the nominal patient (Pn). The results of the other patients (P1-P3) indicate
the significant off-set from the BIS reference point directly linked to the effect
site concentration in (9.9). Both the off-set from the target BIS and the off-
set from the target effect-site concentration is originated from the high inter-
patient variability especially in the PD parameters, Chapter 4, and motivates
the need for a more advanced control strategy.
Performance analysis of control designs CD 1 - CD 4
The RMSE (9.13) is calculated for all control designs CD 1 - CD 4 during
induction (0 min-5 min), BISR = 40 (20 min - 40 min) and BISR = 60 (50 min -
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60 min), to further analyse the presented control strategies. The results are
shown for all patients and all control designs in Figures 9.10 - 9.11.
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Figure 9.10.: RSME for induction (ind.) of anaesthesia, t = 0-5 min.
During induction all control designs seem to perform better for P1 and P2
even compared to the nominal patient, Pn. However, this is related to the
faster response of the patient given by a different sensitivity to the drug. The
significantly worse performance of all controllers for P3 can be explained by
very different dynamics of the system already observed in Figure 9.8.
An accurate comparison the algebraic compensation of the Hill equation and
the piecewise affine linearisation of the Hill equation can only be obtained for
the performance of Pn, as both controllers are designed with identical dynamics
with the patient. Here the algebraic controller CD 1 and CD 2 performs better,
because of the exact approximation of the Hill equation, whereas CD 3 and
CD 4 suffer from a linearisation error, see Figure 9.5.
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Figure 9.11.: RSME during maintenance at BIS = 40 (20 - 30 min) and
BIS = 60 (50 - 60 min) for CD 1-CD 4 and all patients.
The comparison of the control designs during the maintenance phase gives
further insights in the dynamics of the system. Here, the control design based
on the algebraic inverse of the Hill equation shows an excellent performance
(CD 1, CD 2 ) for the nominal patient Pn. Also during induction of anaesthesia,
the piecewise affine linearisation of the Hill equation suffers form the lineari-
sation error, which is minimal at BIS = 60, but more significant at BIS = 40
for the nominal patient, see Figure 9.5. The state estimation by the Kalman
filter in CD 2 and CD 4 improves the performance of the nominal MPC for all
patients, P1 - P3. This is because of a better mapping of the real system’s
states to the measured end-tidal concentration CE , which also is varying con-
siderably depending on the patient’s individual uptake, Figure 9.7. The state
estimation with the Kalman filter can reduce the maintenance off-set. How-
ever, this control strategy is not satisfactory to compensate for the uncertainty
introduced by inter-patient variability in the PD parameters.
The different off-set for the four patients at the two different reference points
BIS = 40 and BIS = 60 is originated from the individual Hill equation (3.21),
which describes the BIS as a function of the effect site concentration. All
three patients show a deviation from the nominal Hill equation depending on
the reference point. This should be considered for the algebraic inverse of
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the Hill equation as well as for the piecewise affine linearisation of the Hill
equation. The individual Hill equations of the three patients, the nominal and
the piecewise affine linear Hill equation are depicted in Figure 9.12.
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Figure 9.12.: Algebraic and piecewise affine Hill equation of the nominal pa-
tient and Hill equations of the three patients for isoflurane based
anaesthesia.
Furthermore one has to consider that the effect site concentration is chang-
ing with individual patient variables and parameters as a function of the PD
parameter ke0 and the arterial concentration Ca, which is determined by the
possibly uncertain PK parameters.
As a conclusion, control designs (CD 1 - CD 4 ) only lead to satisfactory
results when the patient’s parameters are very well known and model uncer-
tainty can be reduced to a minimum as shown for the results of the nominal
patient Pn. This is further motivated by the performance of all controllers for
Patient 3 in Figures 9.13 - 9.14.
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Figure 9.13.: Inlet concentration all CD patient 3.
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Figure 9.14.: BIS patient 3.
9.4.2. MPC with Output Disturbance
In this section an off-set free output feedback design is presented. The dy-
namics of the controller are adjusted to the system via an output disturbance
d in the system model, (8.1).
Given the derived state space matrices for the piecewise affine system all
matrix pairs (A,C) (9.1) are observable. However, the augmented system
with the choice of Bd = 0, ∈ R7×1 and Cd = 1 with nx = 7 and nd = ny = 1,
is not observable, see (8.8). An alternative choice for Bd is challenging and
difficult to define, because the entries are suffering from uncertainties due
to inter-patient variability in the PK and PD variables and parameters that
might not be linearly related. To test the off-set free method via including an
output disturbance, the disturbance estimation is circumvented by assuming
a constant output disturbance dk for the entire horizon given by the difference
of measured output ymk and predicted output yk of the system model.
dk = ymk − yk
dk+1 = dk (9.14)
This disturbance is then incorporated in the formulation of the objective func-
tion in (8.1) and the mp-QP problem, Appendix A, as an output disturbance
to adjust the controller to the patient’s dynamics, (Rawlings and Mayne, 2009,
p. 49):
min
x,y,u
J = N∑
k=1(yk + dk − yRk )′QR(yk + dk − yRk ) (9.15)
The system matrices of all three piece-wise affine systems were evaluated
and they satisfy the condition for the rejection of all disturbances and off-set
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free control (9.14). The design of the controllers is given in Table 9.3.
Table 9.3.: Control design (CD ) for output disturbance MPC.
MPC State Est PD
CD 5 output feedback MPC ‘Perfect’ observer linearised
CD 6 output feedback MPC Kalman filter linearised
To obtain a stable control performance the sampling time was decreased
to ts = 3 seconds and the control horizon and output horizon were increased
accordingly, Table 9.4. All other parameters were set identical to the specifica-
tion in Table 9.2. Because of the high control and output horizon, no explicit
solution was obtained. Therefore the on-line version of the controller, solving
a QP problem, was applied to obtain the simulation results. The derivations
of the explicit and on-line/conventional controller are given in Appendix A.
Table 9.4.: Control design for CD 5-CD 6.
Variable Value
ts 0.05 ≙3 sec
N 20 ≙ 1 min
M 8 ≙ 24 sec
Performance analysis of control designs CD 5 - CD 6
The output feedback design shows a considerably better performance than de-
signs CD 1-CD 4. The RSME during induction, Figure 9.15, and maintenance
for both reference points is reduced, Figure 9.16. Note the different scale in
comparison to Figures 9.10 - 9.11.
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Figure 9.15.: RSME for induction of anaesthesia from t = 0-5 min CD 5 and
CD 6.
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Figure 9.16.: RSME in the maintenance phase for CD 5 and CD 6 BIS=40 from
20-30 min, BIS=60 from 50-60min of anaesthesia.
The simulation results of the closed-loop control performance are shown
in Figures 9.17 - 9.19. The on-line MPC is adjusting the required input to
the patient’s dynamics, based on the measured BIS and maintains a stable
reference point change for all patients.
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Figure 9.17.: Inlet concentration of all patients for CD 5 and CD 6.
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Figure 9.18.: End-tidal concentration of all patients for CD 5 and CD 6.
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Figure 9.19.: Measured BIS of all patients for CD 5 and CD 6.
9.5. Concluding Remarks
The results clearly confirm the need for a robust control method to adjust
the controller’s dynamics to the patient based on an output feedback strategy.
The presented control strategy, including an output disturbance, shows a good
performance for all patients and is able to reduce the off-set of the controller
to an acceptable limit compared to the nominal mp-MPC.
In the next chapter advances towards on-line estimation of the PD parameter
with the highest sensitivity C50 will be investigated.

10. On-line Parameter Estimation
This chapter presents an on-line estimation of the PD parameter C50 as an
alternative method to cope with the high model uncertainty. The intensive
analysis of the model variables and parameters in Chapter 4 led to the con-
clusion that C50 is the parameter with the highest sensitivity and influence
on the BIS. Furthermore due to correlation with the other PD parameters
an estimation of C50 can compensate for a model mismatch resulting from
uncertainty in the other PD parameters and the PK parameters, Table 4.5
and Table 4.4. Hence, it is believed that an on-line estimation of C50 can
compensate model mismatch and provide off-set free reference tracking of the
BIS. This statement is further investigated and an algorithm to estimate C50
on-line is presented in this Chapter.
The strategy of on-line parameter estimation for anaesthesia control was
performed for Propofol by Sartori et al. (2005) and Robayo et al. (2010). In
Robayo et al. (2010) the authors estimated the slope of the linearised Hill
equation at BIS = 50 as a function of the cross correlation between measure-
ment in the intensive care unit and prediction of the BIS. Sartori et al. (2005)
formulated the non-linear PK-PD system and added the parameters C50 and
ke0 as system states. The resulting system was linearised at every step and
the states and parameters were estimated by a Kalman filter. In Sreenivas
et al. (2009) the authors mention an improved prediction of the BIS, when
estimating C50 for isoflurane based anaesthesia, based on the measurement
during induction. However, no method for the estimation of C50 is described
in Sreenivas et al. (2009).
10.1. Control and Algorithm Design
The proposed control design is based on the control design previously presented
in Figure 9.2. An additional block for the on-line estimation of C50 is added
and the resulting control structure is depicted Figure 10.1. The non-linearity
of the Hill equation is compensated by its inverse (9.9) analogously to the
design in Figure 9.2. Hence the reference point of the effect site concentration
CRe is calculated as a function of the reference point on the hypnotic depth
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BISR and the PD parameters C50 and γ in (9.9).
State Estimator
PK
Est.
Cˆe = f (Cˆa)
Controller
MPC
Patient
PK PD
inverse
Hill equation
On-line Parameter Estimator
Patient
PK PDPD
Est
BISR
CRe C
m
e
CI
CI
CI
B̂IS
BISm
BISm
CE
CˆPK Cˆ
Cˆ50
Cˆe
Figure 10.1.: Closed-loop control design for on-line parameter estimation of
C50.
The decision process of the on-line estimator block in Figure 10.1 is illus-
trated in Figure 10.2. The on-line parameter estimator can be switched on or
off. If active, C50 is estimated and updated under the conditions depicted in
the flow chart in Figure 10.2.
Estimate C50: on
∆BIS > ∆BISt > ton
∆t > ∆t
solve (10.2):
Cˆ50,i = min
C50
J
update Cˆ50,i
in (9.9)
∆t = t − t0
yes
yes
yes
yes
t0 = t
no
Figure 10.2.: Decision process of the on-line parameter estimator block.
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The first estimation and update of C50 occurs at least ton min after induction
of anaesthesia, (t > ton). If the on-line parameter estimation is switched on,
the parameter estimation block becomes active, when an error between the
measured BIS, BISm, and the predicted BIS, B̂IS, by the Hill equation with
the current parameters is detected. A mismatch is defined as a deviation of
prediction and measurement of more than ∆BIS during in the last ∆t min,
i.e. ∆BIS > ∆BIS.
∆BIS = 1
n
t∑
i=t−∆t
⎛⎝(BISmi − B̂ISiBISmi )
2⎞⎠
1
2
(10.1)
This triggers the on-line estimation by solving a constrained non-linear least
squares problem. The solution of C50 is obtained by minimising the error
between B̂IS and BISm:
min
C50
J = t∑
i=t−t∆(BISmi − B̂ISi)2
s.t. B̂ISi = BIS0 + (BISmax −BIS0) Cγe,i
Cγ50 +Cγe,i(1 −∆C50) C50,t−1 ≤ C50,t ≤ (1 +∆C50) C50,t−1
C50,min ≤ C50,t ≤ C50,max
(10.2)
Constraints on the change of the estimated value of C50,t aim for a smooth
transition of the parameter to the real value and secure stability against short
term disturbances and/or measurement errors. Before anaesthesia C50,t−1 is
set to its nominal value. Throughout the simulation C50,t is initialised with
its previous estimate C50,t−1. The solution of the estimation problem is con-
strained by ±∆C50 of its previous value C50,t−1 and a lower and upper bound,
C50,min and C50,max, given in Table 3.2. When a feasible and optimal solution
for C50,t of the estimation problem is obtained, the inverse Hill equation (9.9)
is updated with this value after each on-line estimation step. An additional
parameter to enhance a smooth transition of C50 to its real value is the time in-
terval t∆. Only the measurements and predictions in this interval are included
in the on-line parameter estimation problem, (10.2). The least squares esti-
mation problem is solved using GAMS and the global solver BARON (GAMS,
2013). The estimated parameter is send to MATLAB via GDXMRW, (Ferris
et al., 2011).
The design parameters of the presented on-line parameter estimation algo-
rithm and the tuning parameters are summarised in Table 10.1.
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Table 10.1.: On-line parameter estimation tuning parameters and design.
Parameter Value Unit
ton 5 min Minimum time after anesthesia induction
to trigger parameter estimation.
∆BIS 5 % Error to initiate a parameter estimation.
∆t 3 min Time since the last update of the Hill
equation.
t∆ 3 min Past measurements included in the param-
eter estimation problem.
∆C50 20 % vol % Deviation of old and newly estimated
value of C50.
10.2. Evaluation of the On-line Estimation
Algorithm
This strategy is now investigated for Patient 3, because Patient 3 is showing
the highest off-set for all control strategies presented in Chapter 9, Figure 9.8.
The MPC is designed according to the control design CD 1 in Table 9.1. Anal-
ogously to the closed-loop control validation in Section 9.4 the state estimator
and mp-MPC are both based on the derived PK-PD model with nominal pa-
tient values, whereas the patient model is based on individualised variables and
parameters. The control strategy with on-line parameter estimation (ĈD) is
tested for a constant reference point of BISR = 40 for 100 min. The simulation
results are shown in Figures 10.3 - 10.6 for control design CD and ĈD 1.
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Figure 10.3.: Control input for Patient 3 of CD 1 and ĈD.
Chapter 10 117
During the initial 5 minutes, t < ton, both controllers give an identical input,
while after 5 min the input of ĈD is adjusted according to the update of C50
in Figure 10.6. This update triggers a reference point change on the effect site
concentration CRe as a result of the updated value of C50 in the inverse Hill
equation and a more accurate knowledge of the patient’s individual parame-
ters. Figure 10.3 shows the changing inlet concentration of the controller as a
consequence of this reference point change of CRe depicted in Figure 10.4. The
reference concentration CRe is updated with every new estimate of C50.
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Figure 10.4.: CRe and actual Ce for Patient 3 of CD 1 and ĈD.
Figure 10.4 shows a large off-set, which was also reported in Chapter 9 for
control design CD 1 and emphasises the need of an off-set free control design.
This off-set in the effect site concentration originates from different PK and
PD variables and parameters of the nominal patient and Patient 3 and causes
a further off-set in the BIS shown in Figure 10.5.
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Figure 10.5.: BISR and actual BIS for Patient 3 of CD 1 and ĈD.
By the estimation of C50, ĈD converges to the reference point BIS = 40,
Figure 10.5. Likewise the estimated value of C50 converges to a final value of
Cˆ50= 0.647 [vol%].
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Figure 10.6.: Estimated Cˆ50 of ĈD for Patient 3.
To confirm and validate this result of the least squares parameter estimation
(10.2) with GAMS, (GAMS, 2013), a maximum likelihood parameter estima-
tion for nominal values of all the PK and PD variables and initialised with
the nominal value of C50 was performed with gPROMS (PSE, 2011). The
obtained estimated value was C50 = 0.612 [vol%]. This result is reasonably
close to the result obtained by the solution of the least squares problem and
confirms the accuracy of the parameter estimation result with GAMS (2013).
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10.3. Case study: Controller Evaluation for
Isoflurane Based Anaesthesia
The control design of ĈD is now investigated for all three patients undergoing
isoflurane based anaesthesia and described in Section 5.1 for a reference point
change from BIS = 40 to BIS = 60 after 60 min of anaesthesia. The simulation
results of all three patients are shown in Figures 10.7 - 10.10.
During the initial 5 minutes the MPC computes an identical input for all
three patients. After this short induction time C50 of each patient is estimated
individually based on the obtained measurements of the BIS during the last 3
minutes (10.2). This is depicted in Figure 10.9. The estimation of C50 results
in an update of the reference effect site concentration CRe in Figure 10.8. The
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Figure 10.7.: Control input for Patient 1-3 of ĈD.
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Figure 10.8.: CRe and actual Ce for Patient 1-3 of ĈD.
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Figure 10.9.: BISR and actual BIS for Patient 1-3 of ĈD.
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Figure 10.10.: Estimated Cˆ50 of ĈD for Patient 1-3.
measured BIS of all three patients converges to the reference point BISR in
Figure 10.9. The required target effect site concentration to obtain BISR is
varying significantly between patients due to large inter-patient variability,
discussed in detail in Chapter 4. Figure 10.7 shows the individual control
inputs obtained correctly through the individualised parameter estimation of
C50 shown in Figure 10.10.
The estimated values of C50 converge to a constant value in less than 20 min
of anaesthesia. Due to the change in BISR the estimation of C50 is triggered
repeatedly, Figure 10.10. Here the updated parameter, C50, for Patient 3
converges faster to a steady value. C50 of Patient 1 and Patient 2 is re-
peatedly updated every 3 minutes and at the constraint at the lower bound
C50,t ≥ 0.8C50,t−1 is active. This is originated from the different slope of the
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individual Hill equations in Figure 9.12 and the distinct deviation from the
nominal value at BIS = 40 and BIS = 60.
10.4. Concluding Remarks
The on-line estimation of C50 shows promising results towards an individ-
ualised control strategy of anaesthesia. This strategy allows to adjust the
controller to the individual sensitivity of the patient towards the anaesthetic
agent. Furthermore the anaesthetist gains understanding of the patient’s sen-
sitivity, which could be advantageous for future surgeries of the same patient.
The presented strategy is believed to be safe for the patient ensured by con-
straints in the controller configuration and constraints in the parameter esti-
mation problem.
The tuning parameters of this strategy are (i) the permitted deviation from
the initial value for C50 in the parameter estimation problem, which was set to
∆̂C50 = ±20% in this study, (ii) the percentage of deviation from the measured
BIS, which triggers an estimation of C50, set to ∆̂BIS=5% in this study, and
(iii) ∆t the sampling time between each parameter estimation, which was set
to ∆t=3 min.
A first study to investigate the capabilities of the on-line parameter estima-
tion algorithm to reject disturbances is presented in Appendix C.

11. Conclusions and Future
Directions
The framework presented in this thesis and illustrated anew in Figure 11.1
provided a valuable guideline for model development and analysis when aiming
for a robust control strategy and the design of a safe drug delivery system for
anaesthesia.
Modelling
Control
Model AnalyisModel
Uncertainty
Identification
Closed-Loop
Control System
Validation
Robust Control
Strategies
Figure 11.1.: Framework presented in this thesis for volatile anaesthesia.
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11.2. Key Contributions from this Thesis
Part I: Modelling1
▶ Individualised physiologically based pharmacokinetic-pharmacodynamic
model for volatile anaesthesia.
▶ Insights in the model dynamics via analysis of the individualised param-
eters and variables of the derived model.⪧ Envelope of model uncertainty.⪧ Global sensitivity analysis.⪧ Variability analysis.⪧ Correlation analysis.
▶ Validation of the pharmacokinetic part of the model with clinical data
for isoflurane and desflurane based anaesthesia.
▶ Individual estimation of the pharmacodynamic parameters for isoflurane
and desflurane of the Hill equation for each patient.
▶ Capabilities of the model to be applied as teaching tool of drug distri-
bution and drug effect modelling for anaesthesia.
Part II: Model Predictive Control
▶ Testing of the consequence of inter- and intra-patient variability for open-
loop nominal mp-MPC.
1The work presented in Part I has been partly published in Krieger et al. (2013).
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▶ Design of an explicit control strategy, which adjusts to the patient’s
dynamics and enables off-set free control for drug delivery systems for
volatile anaesthesia.
▶ Design of a control strategy which adjusts to the patient’s dynamics by
on-line parameter estimation of the parameter with the highest sensitiv-
ity: C50.
▶ Contribution towards personalised health care by taking into account
the individual patient characteristics.
11.3. Summary of this Thesis
The presented model for volatile anaesthesia combined existing ideas of com-
partmental and physiologically based models for the uptake and distribution
of anaesthesia originated from the work of Mapleson (1963) and Eger (1974).
In the derived model the PK variables and parameters where described as a
function of age, weight, height and gender of the patients to account for indi-
vidual patient characteristics. This strategy was validated by the comparison
of the simulation results with clinical studies for 11 patients and 2 different
anaesthetic agents, 3 patients undergoing isoflurane based anaesthesia and 8
patients undergoing desflurane anaesthesia.
The sequential analysis and grouping of the variables and parameters of
the model in their related PK and PD group led to a good understanding
of the model’s dynamics and the influence of the specific parameters on the
measurable outputs, BIS and CE . (i) The lung volume and the cardiac output
mainly determine the uptake of the drug. (ii) The concentration at 50% drug
effect C50 defines the sensitivity of the patient and therefore the resulting effect
for a fixed effect site concentration. The results for tissue concentrations are
in accordance with the literature, (Eger, 1974, p.89).
The considerably more profound uncertainty in the PD parameters in com-
parison with the PK parameters and variables found in this thesis was previ-
ously reported in the literature (Mertens and Vuyk, 1998).
The model showed good capabilities to serve as a teaching tool and examine
the influence of a variable and/or parameter on the internal drug concentra-
tions and the uptake.
With respect to robust model predictive control, the extensive modelling
process proved to be rewarding, as (i) an underlying model of adequate com-
plexity for control, which is still able to capture the individual patient’s charac-
teristics, was found and (ii) the uncertainty the control strategy has to handle
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was identified.
Based on the model the risks of using a nominal open-loop explicit MPC for a
system that is suffering from such high uncertainty was shown. Consequently,
the design of an output feedback controller, including the model mismatch as
an output disturbance, was developed that adjusts to the patients’ dynamics.
The output feedback controller was derived as an on-line controller, which is
solving a QP problem at each iteration step.
An alternative on-line solution to adjust the controller to the patients’ dy-
namics was the combination of the mp-MPC with an on-line parameter estima-
tor of C50. This design additionally provides the anaesthetist with information
about the patient’s sensitivity.
11.4. Ongoing and Future Work
The derived model showed good results for isoflurane and desflurane and can
be adapted to other volatile anaesthetic agents by changing the solubility
coefficients of the blood and tissue, λ and λi. This encourages further testing
and validation with clinical data of other volatile anaesthetics or the extension
of the model to simultaneous administration more than one anaesthetic agent.
11.4.1. Explicit Model Predictive Control Under Uncertainty
The need for an off-set free and robust control method, because of high inter-
patient variability and the probability of changing variables during surgery,
due to e.g. surgical stimulation, blood loss, blood transfusion, was clearly
shown. The explicit MPC solution provides a excellent testing tool or all
possible scenarios that might occur during anaesthesia. Our current work
is dealing with deriving the explicit form of the output-feedback controller,
for which so far the on-line formulation was tested. Additionally an alterna-
tive to estimate the output disturbance is investigated. Further testing will
be performed for disturbance rejection of disturbances often occurring during
anaesthesia, (Dumont et al., 2009; Struys et al., 2004), and tested in Yelneedi
et al. (2009) for isoflurane. First results are summarised in Appendix C. The
testing and validation of the closed loop control algorithm will be performed
with the platform of the derived model for volatile anaesthesia, which also
might lead to the development of other robust control strategies, such as in-
cluding an integral penalty on the reference tracking error.
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11.4.2. Model Predictive Control for Hybrid Systems
The piecewise affine linearisation of the Hill equation results in three different
controllers, which are switching according to the predicted system output. An
alternative is the formulation of the objective function as a hybrid system,
where the optimal control trajectory can be obtained by dynamic program-
ming, (Rivotti et al., 2012a).
11.4.3. Moving Horizon Estimation
Concerning the state estimation, the application of the ‘perfect’ observer in-
herits the advantage that no infeasibilities of the controller can occur, as con-
troller and estimator are based on the same model. The Kalman filter, how-
ever, showed to improve the performance of the mp-MPC because the states
were estimated based on the measured output and, naturally, closer to the
real states, the internal blood and tissue concentrations. The application of
a moving horizon estimator (MHE) for state estimation combines both ad-
vantages, because of constraint handling on the states, at the cost of a more
difficult implementation, i.e.
min
xˆt−Nˆ ,{wˆ}t−1t−Nˆ J = ∥xˆt−Nˆ − x¯t−Nˆ∥P−1t−Nˆ +
t−1∑
k=t−Nˆ ∥wˆk∥2Q−1k +
t∑
k=t−Nˆ ∥vˆk∥2R−1k
s.t. xt−Nˆ+k+1 = Axt−Nˆ+k +But−Nˆ+k +Gwt−Nˆ+k,
yt−Nˆ+k = Cxt−Nˆ+k +Dut−Nˆ+k + vt−Nˆ+k,
(11.1)
where Nˆ denotes the estimation horizon. Here the computation of the distur-
bance matrix G involves the highest challenge, because it maps coloured noise
on the states, (Findeisen, 1997). As the system itself is uncertain, the choice
of G is more challenging and the influence of a nominal choice of G on the
closed control loop might lead to an unstable system and needs to be further
investigated. The task of finding G is similar to the challenge of determining
Bd in Section 8.2 (8.8) and estimate the output disturbance’s impact on the
system states.
The simultaneous design of the explicit solution of the MHE and the MPC
Voelker et al. (2010, 2013) offers a full explicit solution of the closed control
loop for anaesthesia control that accomplishes the high safety measures for
testing required for the control of a biomedical system such as anaesthesia.
Chapter 11 129
11.4.4. Model Reduction
An alternative strategy in order to obtain an explicit mp-MPC, while main-
taining the system’s dynamics of a complex model, is via model reduction
techniques, (Lambert et al., 2013; Rivotti et al., 2012b).
11.4.5. Linear Parameter Varying Systems
The approach presented in Chang et al. (2013a,b) shows promising results for
LPV systems, while maintaining the explicit solution of the nominal mp-MPC.
The extension of the presented method to a time-varying system matrix Ak
and a time varying system matrix Bk,
xk+1 = Akxk +Bkuk
yk = Cxk, (11.2)
allows to adjust the controller in advance to the varying or knowingly different
PK parameters without the need of deriving an new explicit solution of the
mp-MPC.
11.5. Anaesthesia Automation
Closing the loop of the anaesthetic system implies automatic drug infusion
based on the model predictions and the feedback through the measured patient
variables. Apart from hypnotic depth, anaesthesia is defined by amnesia,
analgesia, muscle relaxation and the maintenance of the vital functions. A
multiple-input multiple-output (MIMO) controller could regulate all of these
variables (Biro, 2013).
11.5.1. Main Challenges
The main challenges to fully automate anaesthesia are, (Absalom et al., 2011;
Struys et al., 2006):
(i) Development of new sensors to measure adequately all variables of inter-
est to the anaesthetist, where challenge is the measurement of amnesia
and analgesia.
(ii) Further evaluation and testing of robust control strategies with respect
to patient safety.
(iii) New development of multiple drug effect interaction models for the design
of MIMO control strategies.
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The lack of reliable sensors is probably the most profound problem. An
adequate measurable signal is essential for the successful design of a process
model; besides the control strategy relies heavily on an accurate feedback of
the patient’s current state. Apart from the BIS, used for most closed loop
applications, the Narcotrend Monitor or auditory evoked potentials are avail-
able. This variety of possible feedback signals and design of models increases
the difficulty of model and control design, because the parameters cannot be
easily projected from one measurement to another, (Bibian et al., 2011; Bruhn
et al., 2006; Kent and Domino, 2009).
The interactions of various drugs administered simultaneously are very com-
plex, anaesthetics e.g suppress awareness and likewise act as a weak analgesic
agent, (Miller et al., 2010). Most simultaneously administered drugs show syn-
ergetic effects, (Hendrickx et al., 2008). These interactions are very different to
distinguish without adequate sensors. Therefore often the desired plasma con-
centration is targeted for the control or modelling strategy, (Kennedy, 2013).
Developed interaction models of two or more drugs, response surface models,
account for synergetic, additive or antagonistic effects, (Minto et al., 2000).
As a natural consequence of the previously mentioned challenges, there are
legitimate safety concerns regarding stability, robustness and disturbance re-
jection with respect to control algorithms designed for anaesthesia, (Luginbu¨hl
et al., 2006).
Nevertheless, Hemmerling et al. (2013) performed a clinical trial, where
anaesthesia, analgesia and muscle relaxation were maintained by automated
simultaneous infusion of propofol, remifentanil and rocuronium, and achieved
a better performance compared to manual control.
The way to the fully automated operation theatre is certainly a long way
to go, but the realisation of an autopilot for anaesthesia drug delivery is ap-
proaching and indeed achievable with a lot of joint research effort in the in-
terdisciplinary areas of sensor development, detailed mathematical modelling
and robust control design.
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A. MPC to mp-QP
A.1. MPC Problem Formulation
The model predictive controller (MPC) is formulated as follows, see also (8.1).
min
x,y,u
J = x′NPxN + N−1∑
k=1 x′kQxk +
N∑
k=1(yk − yRk )′QR(yk − yRk )
+M−1∑
k=0 u′kRuk +
M−1∑
k=0 ∆u′kR1∆uk
s.t. xk+1 = Axk +Buk, A ∈ Rnx×nx , B ∈ Rnu×nx
yk = Cxk, C ∈ Rnx×ny
(A.1)
The MPC problem is formulated as multi-parameteric quadratic programming
(mp-QP) problem of the form:
min
U
J(θ) =1
2
U ′HU + θ′FU + 1
2
θ′Y θ
s.t. GU ≤W +Eθ (A.2)
Note: The last term is not a function of the optimisation variable U and can
therefore be neglected to find the optimal value in U.
Note: The indices in θ are assigned in the following order: θ = [x0, ut−1, ymt , yR]
x0 state vector at beginning of the control horizon
ut−1 control input at previous time step
ym measured process output
yR constant reference point
with Q,P ∈ Rnx×nx , QR ∈ Rny×ny , R ∈ Rnu×nu
The states for the output horizon are given as a function of the states at the
beginning of the control horizon x0 and the inputs u.
xn = Anx0 + n−1∑
k=0An−1−kBuk, ∀n = 1, . . .N − 1 (A.3)
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To reformulate (A.1) as a multi-parametric problem all states are given in the
following matrix form as a function of the optimisation variables U and the
parameters θ in (A.4).
X =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
x1
x2⋮
xN
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
, U =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
u0
u1⋮
uM−1
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(A.4)
X =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
A 0
A2 0
A3 0⋮ ⋮
AN−2 0⋯ ⋯
AN 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=A˜∈RNnx×nθ
θ +
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
B 0 ⋯ 0 0
AB B ⋯ 0 0
A2B AB ⋯ 0 0⋮ ⋮ ⋮ ⋮ ⋮
AM−1B AM−2A ⋯ AB B⋯ ⋯ ⋯ ⋯
AM−1B AM−2A ⋯ AB B
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=B˜∈RNnx×Mnu
U (A.5)
The matrix 0 in A˜ is ∈ R(nθ−nx)×nx . Here the number of tracked outputs is
equal to the number of outputs, in any other case ny is equal to the number
of tracked outputs. The control input is constant for all N>M, therefore the
last row in B˜ is repeated for all N>M, (Goodwin et al., 2005, p. 105).
A.2. Penalty Weights in the Objective Function
The penalty weights on the states x, control inputs u, reference tracking er-
ror (y − yR) and the step change in the input ∆u are added and described
consecutively.
States x
Q˜ = diag(Q, . . . ,Q,P ), ∈ RNnx×Nnx (A.6)
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min
U
J =X ′Q˜X
= (A˜θ + B˜U)′Q˜(A˜θ + B˜U)= θ′A˜′Q˜A˜θ + θ′A˜′Q˜B˜U +U ′B˜′Q˜A˜θ +U ′B˜′Q˜B˜U= θ′A˜′Q˜A˜θ´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶≠f(U)=const+2θ
′A˜′Q˜B˜U +U ′B˜′Q˜B˜U
= 2θ′A˜′Q˜B˜U +U ′B˜′Q˜B˜U= U[B˜′Q˜B˜]U + θ[2A˜′Q˜B˜]U
(A.7)
Hx = 2B˜′Q˜B˜ (A.8)
Fx = 2A˜′Q˜B˜ (A.9)
Inputs u
R˜ = diag(R, . . . ,R), ∈ RMnu×Mnu (A.10)
min
U
J = U ′R˜U (A.11)
Hu = 2R˜ (A.12)
Reference tracking error (y − yR)
Q˜R = diag(QR, . . . ,QR), ∈ RNny×Nny (A.13)
C˜ = diag(C, . . . ,C),RNny×Mnu (A.14)
Y = C˜X (A.15)
Y ∗ ∶= Y − Y R = C˜[A˜θ + B˜U] − ⎡⎢⎢⎢⎢⎢⎢⎣
0 ⋯ 1⋮ ⋮ ⋮
0 ⋯ 1
⎤⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=K˜∈RN×nθ
θ (A.16)
Y ∗ = [C˜A˜ − K˜]´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=L˜ θ + C˜B˜dcurly∶=M˜ U (A.17)
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Note: The index of 1 in K˜ corresponds to the index of the reference point yR
in the parameter vector θ.
min
U
J = (L˜θ + M˜)′Q˜R(L˜θ + M˜)
= (L˜θ + M˜)′Q˜R(L˜θ + M˜)= θ′L˜′Q˜RL˜θ + θ′L˜′Q˜RM˜U +U ′M˜ ′Q˜RL˜θ +U ′M˜ ′Q˜RM˜U= θ′L˜′Q˜RL˜θ´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶≠f(U)=const+2θ
′L˜′Q˜RM˜U +U ′M˜ ′Q˜RM˜U
= 2θ′L˜′Q˜RM˜U +U ′M˜ ′Q˜RM˜U= U[M˜Q˜RM˜]U + θ[2L˜′Q˜RM˜]U
(A.18)
Hy = 2[M˜Q˜RM˜] (A.19)
Fy = 2[L˜′Q˜RM˜] (A.20)
Input step change ∆u
The previous control action u−1 is added to the parameter vector in order to
respect the constraints on ∆u0 with ∆uk ∶= uk − uk−1.
θ = [x0, yR, u−1]′ (A.21)
Therefore an additional line is added to K˜ to account for u−1 in θ.
min
u
J = M−1∑
k=0 ∆u′kR1,k∆uk (A.22)
R˜1 = diag(R1, . . . ,R1), ∈ RMnu×Mnu (A.23)
∆U = [∆u0 ∆u1 ⋯ ∆uM−1]′ (A.24)
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One extra parameter is added to θ: u−1 to determine ∆u0 = u−1 − u0
θ = [. . . , u−1]
∆U =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
0 1 ⋯ 0 0
0 0 ⋯ 0 0
0 0 ⋯ 0 0⋮ ⋮ ⋮ ⋮ ⋮
0 0 ⋯ 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶= N˜
θ +
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 0 0 ⋯ 0 0−1 1 0 ⋯ 0 0
0 −1 1 ⋯ 0 0⋮ ⋮ ⋮ ⋮ ⋮ ⋮
0 0 0 ⋯ −1 1
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶= O˜
U (A.25)
The entry of 1 in O˜ corresponds to the index of u−1 in the parameter vector
θ.
H∆u = N˜ ′R˜1N˜ (A.26)
F∆u = N˜ ′R˜1O˜ (A.27)
Output Disturbance d
A steady-state target calculation is constructed to remove the effects of es-
timated output disturbances, (Muske and Badgwell, 2002; Pannocchia and
Bemporad, 2007). The output disturbance is defined as the difference be-
tween the measurement and the predicted process output and is assumed to
be constant for the entire output horizon.
xk+1 = Axk +Buk
yk = Cxk + dk, with dk = d0,∀k = 0, . . . ,N − 1
d0 = ym0 − y0
(A.28)
The process output at the beginning of the control and output horizon ym0 is
added to the parameter vector θ. Equation (A.15) is updated as follows:
Note: D ∶= (Y m0 − Y0) (A.29)
Y = C˜X, C˜ ∈ RNny×Mnu (A.30)
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Y ∗ ∶= (Y − Y R) + ⎡⎢⎢⎢⎢⎢⎢⎣
d⋮
d
⎤⎥⎥⎥⎥⎥⎥⎦dcurly∶=D
= (Y − Y R) + (Y m0 − Y0)
= (C˜[A˜θ + B˜U] − Y R) +
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
⎡⎢⎢⎢⎢⎢⎢⎣
0 ⋯ 1 0⋮ ⋮ ⋮ ⋮
0 ⋯ 1 0
⎤⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶= Y m0
θ − ⎡⎢⎢⎢⎢⎢⎢⎣
C ⋯ 0⋮ ⋮ ⋮
C ⋯ 0
⎤⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶= Y0
θ
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
= C˜[A˜θ + B˜U] − ⎡⎢⎢⎢⎢⎢⎢⎣
C ⋯ −1 1⋮ ⋮ ⋮ ⋮
C ⋯ −1 1
⎤⎥⎥⎥⎥⎥⎥⎦´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=K˜∈RN×nθ
θ
Y ∗ = [C˜A˜ − K˜]´udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¸udcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymod¶∶=L˜ θ + C˜B˜dcurly∶=M˜ U
(A.31)
Hy = 2[M˜Q˜RM˜] (A.32)
Fy = 2[L˜′Q˜RM˜] (A.33)
A.3. Constraints
The generic form of the constraints is
GU ≤W +Eθ. (A.34)
The constraints on the states x, control inputs u, the output y and the step
change in the input ∆u are added and described consecutively.
Constraints on x
xmin ≤ x1, . . . xN ≤ xmax
xmax ≥ A˜θ + B˜
xmin ≤ A˜θ + B˜ (A.35)
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Gx = ⎡⎢⎢⎢⎢⎣ B˜−B˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nnx]×Mnu (A.36)
Wx = ⎡⎢⎢⎢⎢⎣ xmax−xmin
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nnx]×1 (A.37)
Ex = ⎡⎢⎢⎢⎢⎣−A˜A˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nnx]×[nx+ny] (A.38)
Constraints on u
umin ≤ u0, . . . , uM−1 ≤ umax
umax ≥ U
umin ≤ U (A.39)
Gu = ⎡⎢⎢⎢⎢⎣ I−I
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×Mnu (A.40)
Wu = ⎡⎢⎢⎢⎢⎣ umax−umin
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×1 (A.41)
Eu = ⎡⎢⎢⎢⎢⎣00
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×[nx+ny] (A.42)
Constraints on y
ymin ≤ y1, . . . , yN ≤ ymax
ymax ≥ C˜X = C˜[A˜θ + B˜U] = C˜A˜θ + C˜B˜U
ymin ≤ C˜X = C˜[A˜θ + B˜U] = C˜A˜θ + C˜B˜U (A.43)
Gy = ⎡⎢⎢⎢⎢⎣ C˜B˜−C˜B˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nny]×Mnu (A.44)
Wy = ⎡⎢⎢⎢⎢⎣ ymax−ymin
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nny]×1 (A.45)
Ey = ⎡⎢⎢⎢⎢⎣−C˜A˜C˜A˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Nny]×[nx+ny] (A.46)
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Constraints on ∆uk
∆umin ≤ ∆u0, . . . ,∆uM−1 ≤ ∆umax
∆umax ≥ ∆U
∆umin ≤ ∆U (A.47)
G∆uk = ⎡⎢⎢⎢⎢⎣ N˜−N˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×Mnu (A.48)
W∆uk = ⎡⎢⎢⎢⎢⎣∆umax−∆umin
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×1 (A.49)
E∆uk = ⎡⎢⎢⎢⎢⎣ O˜−O˜
⎤⎥⎥⎥⎥⎦ , ∈ R[2Mnu]×[nx+ny] (A.50)
A.4. Formulation of the Multi-parametric QP
Problem
The optimisation function A.2 is now formulated as follows
H =Hx +Hy +H∆u
F = Fx + Fy + Fu +H∆u (A.51)
with the constraints matrices
G = Gx +Gu +Gy +G∆u
W =Wx +Wu +Wy +W∆u
E = Ex +Eu +Ey +E∆u (A.52)
and can be solved by applying the POP toolbox for MATLAB, (ParOS, 2004).
B. Explicit solution of the mp-MPC
For control design CD 1-CD 2 in Table 9.1 the parameters θ of the mp-QP
problem are defined as follows:
θ = [Ce,0 Cb,V RG,0 Ct,V RG,0 Cb,M,0 Ct,M,0 Cb,F,0 Ct,F,0 CI,−1 CRe ],
(B.1)
where the subscript 0 denotes the start of the control horizon and the sub-
script −1 the previous time point t = 0 − 1. The optimisation variables, for a
control horizon M = 3, are given by
U = [CI,0 CI,1 CI,2]. (B.2)
The solution of the mp-QP problem in (8.1) results in nCR=650 such critical
regions. The function evaluation to obtain the inhaled anesthetic concentra-
tion which is applied, i.e. CI,0, for the initial critical regions passed and a set
point of BISR = 40 are summarised in (B.3), see Figures 9.6, 9.13. All numbers
are rounded to the third decimal place.
CR1,CR9 ∶ CI,0 = CI,−1 + 0.5
CR178,CR215,CR293 ∶ CI,0 = 4
CR211 ∶ CI,0 = −13.325Ce,0 − 0.557Cb,V RG,0 − 0.364Ct,V RG,0− 0.111Cb,M,0 − 0.075Ct,M,0 − 0.003Cb,F,0− 0.002Ct,F,0 + 0.224CI,−1 + 15.441CRe
(B.3)
The critical region CR1 in the 9 dimensional parameter space, θ (B.1), is
given by the polyhedron in (B.4). All numbers are rounded to the third deci-
mal place.
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0.001Cb,V RG,0 + 0.007Cb,M,0 +Ct,M,0 ≤ 9.10
0.001Cb,V RG,0 + 0.009Cb,M,0 +Ct,M,0 + 0.001CI,−1 ≤ 9.12
0.002Cb,V RG,0 + 0.001Ct,V RG,0 + 0.009Cb,M,0 +Ct,M,0 + 0.002CI,−1 ≤ 9.13
0.002Cb,V RG,0 + 0.002Ct,V RG,0 + 0.009Cb,M,0 +Ct,M,0 + 0.004CI,−1 ≤ 9.14
0.003Cb,V RG,0 + 0.003Ct,V RG,0 + 0.009Cb,M,0 +Ct,M,0 + 0.005CI,−1 ≤ 9.14
0.003Cb,V RG,0 + 0.004Ct,V RG,0 + 0.009Cb,M,0 +Ct,M,0 + 0.006CI,−1 ≤ 9.15
0.003Cb,V RG,0 + 0.004Ct,V RG,0 + 0.001Ct,M,0 + 0.011Cb,F,0 +Ct,F,0 + 0.007CI,−1≤ 10.22
Ce,0 + 0.027Cb,V RG,0 + 0.006Ct,V RG,0 + 0.006Cb,M,0 + 0.001Ct,M,0 + 0.021CI,−1≤ 2.329
Ce,0 + 0.041Cb,V RG,0 + 0.019Ct,V RG,0 + 0.008Cb,M,0 + 0.004Ct,M,0+ 0.045CI,−1 ≤ 2.453
Ce,0 + 0.062Cb,V RG,0 + 0.077Ct,V RG,0 + 0.011Cb,M,0 + 0.016Ct,M,0 + 0.137CI,−1≤ 2.824
0.801Ce,0 + 0.042Cb,V RG,0 + 0.039Ct,V RG,0 + 0.008Cb,M,0 + 0.008Ct,M,0+ 0.094CI,−1 −CRe ≤ −0.108
0.767Ce,0 + 0.044Cb,V RG,0 + 0.048Ct,V RG,0 + 0.008Cb,M,0 + 0.010Ct,M,0+ 0.121CI,−1 −CRe ≤ −0.156−Ce,0 ≤ 0
CRe ≤ 2.2−Cb,V RG,0 ≤ 0
Cb,V RG,0 ≤ 10.717−Ct,V RG,0 ≤ 0
Ct,V RG,0 ≤ 17.617−Cb,M,0 ≤ 0
Cb,M,0 ≤ 5.559−Ct,M,0 ≤ 0
Ct,M,0 ≤ 9.076−Cb,F,0 ≤ 0
Cb,F,0 ≤ 5.207−Ct,F,0 ≤ 0−CI,−1 ≤ 0
CI,−1 ≤ 2.50
(B.4)
C. Disturbance Rejection during
Maintenance of Anaesthesia
During maintenance of anesthesia the aim is stable and constant reference
tracking of the target BIS, BISR, set by the anesthetist. The ability of the
control strategies CD 2 in Chapter 9 and ĈD in Chapter 10 to reject typical
disturbances on the BIS occurring during the course of surgery is presented
in this appendix. These disturbance profiles were published by Dumont et al.
(2009) and Struys et al. (2004) and are shown in Figures C.1 - C.2.
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Figure C.1.: Disturbance profile (Dumont et al., 2009; Hahn et al., 2012): A
arousal reflex due to the first surgical incision; B offset slowly
decreases but settles at an onset of 10% due to continuous normal
surgical stimulations; C withdrawal of stimulations during skin-
closing.
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Figure C.2.: Disturbance profile (Struys et al., 2004): A laryn-
goscopy/intubation; B surgical incision followed by no surgical
stimulation; C abrupt stimulus after a period of low stimulation;
D onset of a continuous normal surgical stimulation; E, F, and
G simulate short-lasting, larger stimulations; H withdrawal of
stimulation during closing.
The tuning parameters of the on-line parameter estimator are summarised
in Table C.1. To enable a faster adjustment of the controller’s dynamics to
the measurement ∆t and t∆ were decreased.
Table C.1.: On-line parameter estimation tuning parameters and design.
Parameter Value Unit
ton 1 min Minimum time after anesthesia induction
to trigger parameter estimation.
∆BIS 2 % Error to initiate a parameter estimation.
∆t 1 min Time since the last update of the Hill
equation.
t∆ 30 sec Past measurements included in the param-
eter estimation problem.
∆C50 20 % vol % Deviation of old and newly estimated
value of C50.
The simulated BIS, optimal control input, CI , and estimated C50 for CD 2
and ĈD and the nominal patient Pn during maintenance of anesthesia under
disturbances in Figures C.1 - C.2 are shown in Figures C.3 - C.8.
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Figure C.3.: BIS for disturbance profile in Figure C.1.
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Figure C.4.: CI for disturbance profile in Figure C.1.
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Figure C.5.: Nominal and estimated C50 for Pn for disturbance profile Fig-
ure C.1.
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Figure C.6.: BIS for disturbance profile in Figure C.2.
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Figure C.7.: CI for disturbance profile in Figure C.2.
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Figure C.8.: Nominal and estimated C50 for Pn for disturbance profile in Fig-
ure C.2.
Figure C.3 and Figure C.6 show an improved tracking of the BIS for control
design ĈD compared to the nominal controller CD 2 under external distur-
bances. The control input, CI , is shown in Figure C.4 and Figure C.7. The
varying CI is initiated by estimated value of C50 in Figure C.5 and Figure C.8
and an updated set point.
ĈD shows a better performance for the rejection of both disturbance profiles
compared to the nominal controller, CD 2. For a slowly changing disturbance
ĈD is able to reject the disturbance successfully and steer the system to
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the target reference value, shown in Figure C.3 and Figure C.6. After the
sequences of different disturbances the estimated value of C50 is converging
to its nominal value Figure C.5 and Figure C.8, which further affirms the
accuracy of the on-line parameter estimator.
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C.1. Concluding Remarks
The control strategy ĈD combines mp-MPC and on-line parameter estimation
of C50 to address control of anesthesia under uncertainty.
The control strategy was evaluated in this appendix for disturbance rejection
of commonly occurring disturbances during the course of surgery. Here, the on-
line estimation of C50 showed promising results for slowly varying disturbances.
However, further investigation is needed to guarantee safe and robust control
also during fast acting disturbances.
D. Application of Robust mp-MPC
for LPV systems to Anaesthesia
The work presented in this appendix was submitted for publication in Chang
et al. (2013b). The solution of a multi-parametric model predictive control
(mp-MPC) problem for linear time-invariant (LTI) systems is extended to
discrete-time linear parameter-varying (LPV) systems, (Chang et al., 2013a).
The method presented in Chang et al. (2013a) and in Chang et al. (2013b)
yields a controller that takes parameter changes into account. This work
addresses a robust performance of mp-MPC applied to LPV systems. This
method can be implemented conveniently as an add-on to the mp-MPC design.
No modification of the established mp-MPC algorithm for LTI systems is
required and the simple computational steps can be implemented on-line.
The presented approach for LPV systems is applied to the biomedical ap-
plication of anaesthesia control. The control objective during anaesthesia is to
provide adequate hypnosis for the individual patient undergoing surgery. This
objective is obtained by continuous intravenous infusion of the anaesthetic
agent propofol, while the hypnotic depth is monitored by the Bispectral Index
(BIS). In the presented example for the control of intravenous anaesthesia, the
time varying system matrix mimics an external disturbance on the output.
D.1. Intravenous Anaesthesia Model
The first step in order to derive a model predictive controller is the choice of
an adequate model of the system. The depth of anaesthesia is monitored by
the Bispectral Index (BIS) calculated as a function of the patient’s electroen-
cephalogram. The objective of the model is to link the BIS to the propofol
infusion. The model predictive control strategy optimises the optimal propo-
fol infusion in order to obtain the desired BIS for a safe depth of anaesthesia.
The equation most commonly used to calculate the BIS is the Hill equation:
BIS = BIS0 + (BISmax −BIS0) (xe)γ(C50)γ + (xe)γ , (D.1)
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here C50 is the concentration triggering 50% of the total effect and γ the slope
of the Hill equation. BIS0 = 100 describes a fully awake patient at zero drug
concentration and BISmax describes the maximum possible effect, BISmax = 0,
(Schnider et al., 1999). xe denotes the effect-site concentration, which is mim-
icking the delay of the drug effect and determined as follows:
dxe
dt
= ke0(x1 − xe), (D.2)
where the rate constant ke0 describes the time delay between plasma x1 and
effect-site concentration xe. The link of the intravenous propofol infusion to
the plasma concentration x1 is described by a commonly used and validated
pharmacokinetic model for propofol distribution. The individualised model
for the specific patient’s characteristics is adapted from Schu¨ttler and Ihmsen
(2000).
For the presented case study the three compartmental pharmacokinetic
model in Schu¨ttler and Ihmsen (2000) for propofol distribution (PK3) was
reduced to a two compartmental pharmacokinetic model (PK2).
dx1
dt
= −(k01 + k12)x1 + k21x2 + m
V1
u,
dx2
dt
= k12x1 − k21x2, (D.3)
where the concentration in the plasma is denoted with x1 and the concen-
tration in the peripheral tissue with x2. The metabolism of propofol in the
plasma is denoted by k10 and the distribution from plasma 1 to peripheral
tissue 2 and vice versa is denoted by k12 and k21, respectively. The volume
of the plasma compartment is denoted by V1 and m is the body weight of the
patient, (Schu¨ttler and Ihmsen, 2000). The parameters k10, k12 and k21 (D.3)
were estimated in order to fit the dynamics of the PK3 model by Schu¨ttler
and Ihmsen (2000). All values of the here presented model for a standard
male patient and the estimated parameter values of the PK2 and the original
parameter values of the PK3 model are summarised in Table D.1.
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Table D.1.: Parameter list of the intravenous anaesthesia model for propofol.
Parameter PK2 PK3 Units Ref.
V1 8840 mL
m 68 kg
age 30 years
k10 0.232 0.162 min
−1 Schu¨ttler and Ihmsen (2000)
k12 0.282 0.246 min
−1 Schu¨ttler and Ihmsen (2000)
k21 0.041 0.053 min
−1 Schu¨ttler and Ihmsen (2000)
ke0 0.456 min
−1 Schnider et al. (1999)
γ 3.19 - Schnider et al. (1999)
C50 1.68 µg mL Schnider et al. (1999)
BIS0 100 - Schnider et al. (1999)
BISmax 0 - Schnider et al. (1999)
The output of interest is the effect site concentration xe (D.2), as it is directly
linked to the hypnotic effect and the BIS (D.1); the effect site concentration xe
of the original PK3 model and the reduced PK2 model is shown in Figure D.1.
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Figure D.1.: Effect site concentration xe of the PK3 and PK2 used in this
study. The input profile of u for the shown simulation is u= 50µg
min−1 for 0 min ≤ t ≤ 60 min and u= 0 for 60 min< t≤80 min.
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Figure D.2.: The error of Figure D.1 (i.e. PK3 − PK2) in percentage.
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The continuous state space model for propofol distribution and effect, which
is described by (D.2) and (D.3), is formulated as follows:
x˙ = Ax +Bu
y = Cx, (D.4)
where the matrices of the continuous state space system are:
A = ⎡⎢⎢⎢⎢⎢⎢⎣
−(k10 + k12) k21 0
k12 −k21 0
ke0 0 −ke0
⎤⎥⎥⎥⎥⎥⎥⎦ ,
B = [m
V1
0 0]′ , C = [0 0 1] .
The states of the system x are x = [x1 x2 xe], where x1, the concentration
of the plasma compartment 1, x2, is the concentration of the peripheral com-
partment 2 and xe is the effect site concentration. All concentrations are given
in [µg mL−1]. The propofol infusion u is given in [µg min−1].
In order to bypass for the non-linearity of (D.1), the target effect site con-
centration xe, which leads to the desired BIS, is calculated by the inverse Hill
equation (D.5) for the control strategy described in the next section,
xe = C50 ( BIS −BIS0
BISmax −BIS )1/γ . (D.5)
D.2. Multi-parametric Model Predictive Controller
for the Anaesthesia LTI System
In this section the explicit mp-MPC controller to obtain the desired BIS by
targeting the effect-site concentration xe is derived. The control objective is
to achieve a fast onset of anaesthesia and maintain a stable hypnotic level,
indicated by BIS = 50. The inverse Hill equation (D.5) with the parameters of
the patient in this case study, Table D.1, gives xe = 1.68 [µg mL
−1] for BIS = 50
as an equivalent set point (yR).
In order to derive the mp-MPC the continuous-time model (D.4) is first
discretised with sampling time ts = 30 seconds. The resulting discrete time
state space representation is formulated as follows:
x(t + 1) = Aˆx(t) +Bu(t),
y(t) = Cx(t), (D.6)
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Aˆ = ⎡⎢⎢⎢⎢⎢⎢⎣
0.7745 0.0179 0
0.1231 0.981 0
0.179 0.001978 0.7961
⎤⎥⎥⎥⎥⎥⎥⎦ ,
B = ⎡⎢⎢⎢⎢⎢⎢⎣
0.003493
0.000255
0.0003847
⎤⎥⎥⎥⎥⎥⎥⎦ and C = [0 0 1] ,
where Aˆ denotes the time invariant discrete system matrix.
This linear MPC reference tracking problem for system (D.6) is formulated
as a constrained optimisation problem with constraints on the states x, out-
put y and input u as follows:
min
U
J = min
U
(x′t+NPxt+N + N−1∑
k=0 u′t+kRut+k +
N∑
k=1(yt+k − yR)′Qy(yt+k − yR))
s.t.
xt+k+1 = Aˆxt+k +But+k, k = 0, . . . ,N − 1,
yt+k = Cxt+k, k = 1, . . . ,N,[0 0 0]′ ≤ xt+k ≤ [6 45 6]′, k = 1, . . . ,N,
0 ≤ yt+k ≤ 6, k = 1, . . . ,N,
0 ≤ ut+k ≤ 200, k = 0,1, . . . ,N − 1,
(D.7)
where U = {u(t), u(t+1), . . . , u(t+N −1)}, N = 6 (3 min), Qy = 106, R = 1, and
P the solution of the algebraic Riccati equation, P = Aˆ′PAˆ−(Aˆ′PB)(B′PB+
I)−1(Aˆ′PB)′.
The constrained optimisation problem (D.7) is reformulated as an mp-QP
problem (8.2). The optimal control law u is obtained as by affine functions
of the parameters, the system states and the set-point (yR), by the POP
MATLAB toolbox, (ParOS, 2004). The solution of the mp-QP problem results
in 108 polyhedral critical regions, (8.3).
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Figure D.3.: Closed loop response for the reference tracking linear MPC of the
LTI system as a solution of the mp-QP in (D.7).
The closed loop response for the reference tracking linear MPC of the LTI
system is shown in Figure D.3. The optimal control trajectory for u is cal-
culated by affine functions of the system states as a solution of the mp-QP
(D.7) from initial condition x(0) = [x1(0) x2(0) xe(0)]′ = [0 0 0]′ and set-
point BIS = 50, Figure D.3(c)). The control objective of a fast induction, low
overshoot and stable maintenance of a BIS = 50 is successfully achieved by a
fast regulation of the effect site-concentration xe to the calculated set-point
xe,SP = 1.68 [µg mL
−1], Figure D.3(a) and Figure D.3(b)), respectively.
D.3. LPV for Disturbance Rejection During
Anaesthesia
During anaesthesia surgical stimulation might act as an external disturbance
on the controlled variable, the BIS. For this case study the disturbance is
modelled by a slowly time-varying matrix A(t) of the system (D.6), where
element A1,1(t) is given as a function of time, i.e.
A(t) = ⎡⎢⎢⎢⎢⎢⎢⎣
A1,1(t) 0.0179 0
0.1231 0.981 0
0.179 0.001978 0.7961
⎤⎥⎥⎥⎥⎥⎥⎦ . (D.8)
The slow change of the system parameter A1,1 of up to 50% in magnitude
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is given by as follows
A1,1(t) = Aˆ1,1 (1 − 0.5 sin(pit
30
)) , 15 ≤ t ≤ 45
A1,1(t) = Aˆ1,1, t < 15, t > 45. (D.9)
The change of the value of A1,1 in matrix A(t) is shown in Figure D.4.
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Figure D.4.: Change of A1,1(t) of the LPV system.
The emerging disturbance profile of the BIS which results from (D.9) is
shown in Figure D.5(a). The effect of the variation on the states x is shown
in Figure D.5(b) and D.5(c).
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Figure D.5.: Disturbance profile of BIS and effect on system states x for the
given variation in A1,1(t) (D.9). The system is initialised at
steady state for a constant propofol infusion of u= 50µg min−1.
The error compensation scheme for LPV systems presented in Chang et al.
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(2013b) is applied to assure safe hypnosis, indicated by a BIS = 50, for this
LPV system.
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(a) Bispectral Index (BIS).
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(b) Effect site-concentration xe.
0 10 20 30 40 50 600
50
100
150
200
Time [min]
u
 [µ
g 
m
in
−
1 ]
 
 
uLTI
uLPV
(c) Propofol infusion u.
Figure D.6.: Closed loop response of the mp-MPC for LTI systems (LTI) and
the mp-MPC for LPV systems (LPV) for the LPV system (D.6)
with A(t) (D.8).
Figure D.6 shows the closed loop response for LPV system with time-varying
matrix A(t) for the LTI and LPV mp-MPC. Analogously to the simulation
shown Figure D.3, all states are initialised with zero and the set-point is
BIS = 50. The proposed error compensation mp-MPC is able to cope with
the LPV system and maintains the system closer to the set-points compared
to the LTI mp-MPC. Overall the proposed method shows promising results
for a 50% reduction in A1,1. The application of the mp-MPC for LPV im-
proved the control performance by approximately 60% compared to the LTI
mp-MPC.
D.4. Concluding Remarks
The LPV mp-MCP framework was tested for a case study for depth of anaes-
thesia control by intravenous anaesthesia, where the time variation in the
system matrix A described a disturbance due to surgical simulation. The
proposed LPV mp-MPC framework showed promising results and steered the
system closer to the target set-points compared to the LTI based mp-MPC.
The LPV method shows a 60% improvement compared to the mp-MPC for
LTI systems.
The presented LPV mp-MPC framework will be further tested in our future
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work for a more complex model of anaesthesia, including a wider range of
disturbances modelled as variations in the system matrix A that are known to
occur during surgery.
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